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A B S T R A C T
Background
Gonadotrophin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent
a luteinising hormone surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the
chances of live birth.
Objectives
To evaluate the effectiveness of the different GnRHa protocols as adjuncts to COH in women undergoing ART cycles.
Search methods
We searched the following databases from inception toApril 2015: theCochraneMenstrualDisorders and SubfertilityGroup Specialised
Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2015, Issue 3), MEDLINE,
EMBASE, CINAHL, PsycINFO, and registries of ongoing trials. Reference lists of relevant articles were also searched.
Selection criteria
We included randomised controlled trials (RCTs) comparing any two protocols of GnRHa used in in vitro fertilisation (IVF) or
intracytoplasmic sperm injection (ICSI) cycles in subfertile women.
Data collection and analysis
Two review authors independently selected studies, assessed trial eligibility and risk of bias, and extracted the data. The primary
outcome measure was number of live births or ongoing pregnancies per woman/couple randomised. Secondary outcome measures were
number of clinical pregnancies, number of oocytes retrieved, dose of gonadotrophins used, adverse effects (pregnancy losses, ovarian
hyperstimulation, cycle cancellation, and premature luteinising hormone (LH) surges), and cost and acceptability of the regimens. We
combined data to calculate odds ratios (OR) for dichotomous variables and mean differences (MD) for continuous variables, with 95%
confidence intervals (CIs). We assessed statistical heterogeneity using the I² statistic. We assessed the overall quality of the evidence for
the main comparisons using ’Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) methods.
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Main results
We included 37 RCTs (3872 women), one ongoing trial, and one trial awaiting classification. These trials made nine different
comparisons between protocols. Twenty of the RCTs compared long protocols and short protocols. Only 19/37 RCTs reported live
birth or ongoing pregnancy.
There was no conclusive evidence of a difference between a long protocol and a short protocol in live birth and ongoing pregnancy rates
(OR 1.30, 95% CI 0.94 to 1.81; 12 RCTs, n = 976 women, I² = 15%, low quality evidence). Our findings suggest that in a population
in which 14% of women achieve live birth or ongoing pregnancy using a short protocol, between 13% and 23% will achieve live birth
or ongoing pregnancy using a long protocol. There was evidence of an increase in clinical pregnancy rates (OR 1.50, 95% CI 1.18 to
1.92; 20 RCTs, n = 1643 women, I² = 27%, moderate quality evidence) associated with the use of a long protocol.
There was no evidence of a difference between the groups in terms of live birth and ongoing pregnancy rates when the following GnRHa
protocols were compared: long versus ultrashort protocol (OR 1.78, 95% CI 0.72 to 4.36; one RCT, n = 150 women, low quality
evidence), long luteal versus long follicular phase protocol (OR 1.89, 95% CI 0.87 to 4.10; one RCT, n = 223 women, low quality
evidence), when GnRHa was stopped versus when it was continued (OR 0.75, 95% CI 0.42 to 1.33; three RCTs, n = 290 women, I²
= 0%, low quality evidence), when the dose of GnRHa was reduced versus when the same dose was continued (OR 1.02, 95% CI 0.68
to 1.52; four RCTs, n = 407 women, I² = 0%, low quality evidence), when GnRHa was discontinued versus continued after human
chorionic gonadotrophin (HCG) administration in the long protocol (OR 0.89, 95% CI 0.49 to 1.64; one RCT, n = 181 women, low
quality evidence), and when administration of GnRHa lasted for two versus three weeks before stimulation (OR 1.14, 95% CI 0.49
to 2.68; one RCT, n = 85 women, low quality evidence). Our primary outcomes were not reported for any other comparisons.
Regarding adverse events, there were insufficient data to enable us to reach any conclusions except about the cycle cancellation rate.
There was no conclusive evidence of a difference in cycle cancellation rate (OR 0.95, 95% CI 0.59 to 1.55; 11 RCTs, n = 1026 women,
I² = 42%, low quality evidence) when a long protocol was compared with a short protocol. This suggests that in a population in which
9% of women would have their cycles cancelled using a short protocol, between 5.5% and 14% will have cancelled cycles when using
a long protocol.
The quality of the evidence ranged from moderate to low. The main limitations in the evidence were failure to report live birth or
ongoing pregnancy, poor reporting of methods in the primary studies, and imprecise findings due to lack of data. Only 10 of the 37
included studies were conducted within the last 10 years.
Authors’ conclusions
When long GnRHa protocols and short GnRHa protocols were compared, we found no conclusive evidence of a difference in live birth
and ongoing pregnancy rates, but there was moderate quality evidence of higher clinical pregnancy rates in the long protocol group.
None of the other analyses showed any evidence of a difference in birth or pregnancy outcomes between the protocols compared. There
was insufficient evidence to make any conclusions regarding adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Gonadotrophin-releasing hormone agonists (GnRHa) used as an adjuvant to gonadotrophins in assisted reproduction treat-
ments
Review question
Researchers from the Cochrane Collaboration reviewed the evidence about the most effective way of using gonadotrophin-releasing
hormone agonists (GnRHa) as part of controlled ovarian stimulation in women undergoing assisted reproduction technology (ART).
Background
GnRHa are given along with hormone injections that stimulate the ovaries, in an attempt to prevent spontaneous release of eggs prior
to their planned surgical retrieval. GnRHa have been proven to improve pregnancy rates; however, various regimens are described in
the literature. We conducted this review to identify the most effective regimens.
Study characteristics
We found 37 randomised controlled trials (RCTs) of 3872 women comparing the use of GnRHa in various protocols. Twenty of these
RCTs (1643 women) compared a long protocol with a short protocol. The evidence is current to April 2015.
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Key results
In comparisons of long GnRHa protocols (where GnRHa is given for at least 14 days prior to the start of ovarian stimulation) versus
short GnRHa protocols (when the GnRHa is given at the start of stimulation) there was no conclusive evidence of a difference in
live birth and ongoing pregnancy rates. However there was moderate quality evidence of higher clinical pregnancy rates in the long
protocol groups. Our findings suggest that in a population in which 14% of women achieve live birth or ongoing pregnancy using a
short protocol, between 13% and 23% will achieve live birth or ongoing pregnancy using a long protocol.
None of the other analyses showed any evidence of a difference in birth or pregnancy outcomes between the protocols compared.
There was insufficient evidence to make any conclusions regarding adverse effects. Further research is needed to determine which long
protocol is most cost effective and acceptable to women.
Quality of the evidence
The quality of the evidence ranged from moderate to low. The main limitations in the evidence were failure to report live birth or
ongoing pregnancy, poor reporting of methods in the primary studies, and imprecise findings due to lack of data. Only 10 of the 37
included studies were conducted within the last 10 years.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Long protocol compared with short protocol for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol
Comparison: short protocol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Short protocol Long protocol
Live birth or ongoing
pregnancies
per woman randomised
138 per 1000 172 per 1000
(131 to 225)
OR 1.3
(0.94 to 1.81)
976
(12 studies)
⊕⊕©©
Low¹,²
No evidence of a differ-
ence between the groups
Clinical pregnancies
per woman randomised
137 per 1000 192 per 1000
(158 to 232)
OR 1.5
(1.18 to 1.9)
1643
(20 studies)
⊕⊕⊕©
Moderate¹
Benefit to long protocol
group
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹High risk of bias associated with poor reporting of methods in the primary studies.
²Imprecision: the confidence interval is compatible with benefit in one or both groups or with no effect.
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B A C K G R O U N D
Description of the condition
Subfertility affects one in seven couples; a high proportion of them
use assisted reproductive technology (ART) in an attempt to im-
prove their chances of conception (Maheshwari 2008). In a natural
cycle, only one oocyte is normally produced. Conversely, an ART
cycle usually aims to produce more than one oocyte destined for
fertilisation, to improve the chances of having a sufficient number
of embryos to choose from.Concurrently, it is crucial to prevent an
excessive response from the ovaries resulting in ovarian hyperstim-
ulation. In order to produce more oocytes, the ovaries are stimu-
lated with high doses of gonadotrophins. However, there is a risk
of a premature surge of luteinising hormone (LH), which could
disrupt both normal follicle and oocyte development, resulting in
non-recovery of oocytes. The incorporation of gonadotrophin-re-
leasing hormone agonists (GnRHa) in controlled ovarian hyper-
stimulation (COH) protocols has been used in ART to reversibly
block pituitary function and prevent a premature LH surge. Use
of GnRHa has resulted in significant improvements in treatment,
including decreased cancellation of started treatment cycles prior
to oocyte recovery and higher pregnancy rates (Fields 2013).
Description of the intervention
Different GnRHa drugs, routes of administration (nasal or sys-
temic), and GnRHa protocols have been used in ART. There are
three main protocols involving GnRHa administration, namely,
the long, the short, and the ultrashort protocol.
• Long protocol: GnRHa is administered at least two weeks
before starting stimulation (to achieve suppression of the ovarian
activity) and continued up until human chorionic gonadotrophin
(HCG) is given, starting from either the second day of the
menstrual cycle (long follicular protocol) or the mid-luteal phase
(21st day) of the previous cycle (long luteal protocol).
• Short protocol: GnRHa is administered from day one or
two of the cycle (day one being the start of the menstrual bleed)
and continued with stimulation until the day of HCG
administration.
• Ultrashort protocol: GnRHa is given for three days, from
day two of the cycle (hence, using only the flare-up effect).
How the intervention might work
Administration of multiple doses of GnRHa causes a reversible
blockade of pituitary function after an initial stimulatory phase,
the so-called flare effect. GnRHa suppresses GnRH receptors and
causes inhibition of postreceptor events (Daya 2000). The result-
ing reduction in bioactive LH levels in the serum (Regan 1990)
allows multiple follicular development to continue (until ready
for oocyte recovery) avoiding the risk of a LH surge and hence
premature ovulation (Barlow 1998).
GnRHa are the most commonly used adjuvants for con-
trolled ovarian stimulation (www.ivf-worldwide.com/survey/
survey). Traditionally, the long protocol involves GnRHa use dur-
ing the entire stimulation phase until HCG administration. Re-
ports showed that low endogenous LH concentrations persist until
10 to 14 days after discontinuation of the GnRHa (Donderwinkel
1993; Sungurtekin 1995). Earlier studies have argued that con-
tinuation of GnRHa during the stimulation phase can also lead to
profound suppression of mid-follicular LH, which might be asso-
ciated with early pregnancy loss (Westergaard 2000). Therefore,
GnRHa could be stopped earlier in the long protocol stimulation
cycle (Simons 2005), allowing the pituitary to recover in time for
the luteal phase without risking a premature LH surge. This could
reduce both cost and inconvenience as fewer injections would be
needed.
Why it is important to do this review
The original Cochrane review on the topic, published in 1998
and updated in 2009, showed superiority of the long protocols
compared with the short or ultrashort protocols. Of note, long
protocols are traditionally used in ART, whereas most of the newer
alternatives (e.g., antagonists or mild protocols) have been com-
pared with them (Mancini 2011; Mohsen 2013). The second up-
date of this review aimed to examine whether evidence in the last
three years on the relative effectiveness of the different GnRHa
protocols used as adjuncts to hormonal ovarian stimulation for
ART supports the conclusions of the first update.
O B J E C T I V E S
To evaluate the effectiveness of the different GnRHa protocols as
adjuncts to COH in women undergoing ART cycles.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) comparing various go-
nadotrophin-releasing hormone agonist protocols in assisted re-
productive technology (ART). We included in vitro fertilisation
(IVF) or intracytoplasmic sperm injection (ICSI) treatment cy-
cles. We excluded trials if we found allocation to be non-random
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as they are associated with a high risk of bias. We also excluded
cross-over trials as the design is not suitable for this review. We
excluded quasi-randomised trials even if they had been included
in the original review.
Types of participants
Women/couples with all types of infertility were eligible for in-
clusion, undergoing ART and using GnRHa for pituitary down-
regulation.
Types of interventions
Inclusion criteria
Studies comparing any two protocols using gonadotrophin-releas-
ing hormone agonists (GnRHa) for pituitary suppression in an
ART programme. We included ultrashort, short, and long (follic-
ular or luteal with or without discontinuation during the stimu-
lation phase) protocols.
The definitions used in this review for the various protocols were
as follows.
• Long protocol: GnRHa commenced at least two weeks
before starting stimulation and continued up until human
chorionic gonadotrophin (HCG) was given.
• Short protocol: GnRHa commenced at the same time as
starting stimulation and continued up until the day of HCG
administration.
• Ultrashort protocol: stimulation was commenced one to
two days after starting GnRHa (and given only for three days).
Exclusion criteria
We excluded women receiving donor oocytes.
We also excluded the following study comparisons.
1. GnRHa versus GnRH-antagonist protocols.
2. Different routes of administration of GnRHa.
3. GnRHa versus placebo protocols (Hughes 1992).
4. Depot versus daily administration of GnRHa, as this is the
topic of another Cochrane review (Albuquerque 2013).
5. Addition of any drug in GnRHa protocols.
Types of outcome measures
Wemeasured the following primary and secondary outcome mea-
sures.
Primary outcomes
1. Number of live births or ongoing pregnancies per woman/
couple randomised.
We defined live birth as the delivery of a live foetus after 20 com-
pleted weeks of gestational age. We defined ongoing pregnancy as
evidence of a gestational sac with foetal heart motion at 12 weeks
or later, confirmed with an ultrasound. We decided to combine
the two outcomes, as ongoing pregnancy comprises a more mean-
ingful clinical measure compared with any other and in order to
give more power to the results of the current update.
When there were multiple live births (e.g., twins or triplets), we
counted these as one live birth event.
Secondary outcomes
1. Number of clinical pregnancies per woman/couple
randomised, defined as evidence of a gestational sac with foetal
heart motion at six weeks or later, confirmed with an ultrasound.
When there were multiple gestational sacs in one woman, we
counted these as one clinical pregnancy (Griffin 2002).
2. Number of oocytes retrieved per woman randomised.
3. Amount of gonadotrophins administered per woman
randomised.
Adverse outcomes
1. Number of pregnancy losses, defined as the sum of the
number of miscarriages (pregnancy loss before 20 completed
weeks of gestation) and the number of stillbirths (pregnancy loss
after 20 completed weeks of gestation) (Griffin 2002).
2. Number of ovarian hyperstimulation syndrome (OHSS)
events per woman randomised.
3. Cycle cancellation (defined as cancelled cycle before oocyte
retrieval).
4. Number of premature luteinising hormone (LH) surges.
Other outcomes
1. Cost of treatment.
2. Acceptability of the regimen.
Search methods for identification of studies
We analysed all published and unpublished RCTs comparing the
various regiments for pituitary down-regulation using GnRHa
in ART without language restriction and in consultation with
the Menstrual Disorders and Subfertility Group (MDSG) Trials
Search Co-ordinator.
Electronic searches
We searched the following databases on 23 April 2015, using the
search strategy developed by the Menstrual Disorders and Subfer-
tility Group:
• the Cochrane Menstrual Disorders and Subfertility Group
(MDSG) Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (Issue 3, 2015);
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• MEDLINE;
• EMBASE;
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature); and
• PsycINFO.
The searches were conducted using the search strategies listed in
the appendices (Appendix 1; Appendix 2; Appendix 3; Appendix
4; Appendix 5).
Searching other resources
We searched the citation lists of relevant publications, review arti-
cles, abstracts of scientific meetings, and included studies. In liai-
son with the Trials Search Co-ordinator, we included in the review
published articles and conference abstracts that are not covered in
the Menstrual Disorders and Subfertility Group Specialised Reg-
ister. In addition, OpenGrey, a system for grey literature produced
in Europe, such as research reports, doctoral dissertations, and
conference papers (www.opengrey.eu/), was searched.
We searched the following trials registries for published, ongoing,
or registered trials:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register, a service of the US National Institutes of Health (
clinicaltrials.gov/ct2/home).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch/Default.aspx).
Data collection and analysis
Selection of studies
Four review authors (AM, CS, AG, and GB), in pairs, indepen-
dently selected the trials for inclusion using forms designed ac-
cording to Cochrane guidelines. We sought, via e-mail, additional
information on trial methodology and missing data from the au-
thors of trials that appeared to meet the eligibility criteria but had
unclear methodology or data that were in an unsuitable form for
meta-analysis. Discussion with SB resolved differences of opinion.
We documented the selection process with a ’Preferred Reporting
Items for Systematic Reviews and Meta-Analyses’ (PRISMA) flow
chart (Figure 1).
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Figure 1. Study flow diagram.
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We constructed ’Characteristics of included studies’ tables for
those trials considered suitable for inclusion (Characteristics of
included studies). The ’Characteristics of excluded studies’ tables
list the excluded studies with reasons for exclusion (Characteristics
of excluded studies).
Data extraction and management
Two review authors (AG and GB) independently extracted data
from eligible studies using a data extraction form, which we had
designed and pilot tested. A third review author (CS) resolved
disagreements. Data extracted included study characteristics and
outcome data. Where studies had multiple publications, we col-
lated the multiple reports of the same study, so that each study
- rather than each report - was the unit of interest in the review,
and such studies have a single study identification with multiple
references. As required, we corresponded with study investigators
for further data on methods, results, or both, via e-mail.
The data extraction forms included ’Risk of bias’ criteria
and methodological details, which we have presented in the
’Characteristics of included studies’ tables. We managed the data
using Review Manager 5.3 software (RevMan 2014).
Appendix 6 shows the information extracted from the studies se-
lected for the review.
Assessment of risk of bias in included studies
Two review authors (AG and GB) independently assessed the in-
cluded studies for risk of bias using Cochrane’s ’Risk of bias’ as-
sessment tool (Higgins 2011) to assess selection bias (random se-
quence generation and allocation concealment), performance bias
(blinding of participants andpersonnel), attrition bias (incomplete
outcome data), reporting bias (selective reporting), and other bias.
A third review author (CS) resolved disagreements. We described
all judgements fully and presented them in the ’Characteristics of
included studies’ tables, including commentary about each of the
domains. This led to an overall assessment of the risk of bias of
included studies (Figure 2 and Figure 3).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
We searched for within-trial selective reporting, such as trials fail-
ing to report obvious outcomes or reporting them in insufficient
detail to allow inclusion. We sought published protocols and com-
pared the outcomes between the protocol and the final published
study.
Measures of treatment effect
For dichotomous data (e.g., live birth and ongoing pregnancy
rates), we used the numbers of events in the control and interven-
tion groups of each study to calculateMantel-Haenszel odds ratios
(ORs). For continuous data (e.g., number of oocytes retrieved), we
calculated the mean difference (MD) between treatment groups.
We presented 95% confidence intervals for all outcomes. Where
data to calculate ORs or MDs were not available, our intention
was to utilise themost detailed numerical data available that might
facilitate similar analyses of included studies (e.g., test statistics, P
values). We compared the magnitude and direction of effect re-
ported by studies with how they are presented in the review, taking
account of legitimate differences.
Unit of analysis issues
The primary analysis was per woman randomised; we included
per-pregnancy data for some outcomes (e.g., miscarriage). We
countedmultiple live births (e.g., twins or triplets) as one live birth
event.
Dealing with missing data
In the case of missing data in the included studies, we contacted
the original investigators by e-mail or post to request relevant
missing information. (We sent a reminder if we had received no
reply during the first 20 days.) We reported the data according to
intention-to-treat principles wherever possible. We assumed that
live births had not occurred in participants without a reported
outcome. For other outcomes, we analysed only the available data.
If studies reported sufficient detail to calculate MDs but provided
no information on the associated standard deviation (SD), we
assumed the outcome to have a SD equal to the highest SD from
other studies within the same analysis.
Assessment of heterogeneity
Before any meta-analysis was done, we judged whether there was
sufficient similarity between the eligible studies in their design
and clinical characteristics to ensure that pooling was valid. We
assessed statistical heterogeneity in the results of trials by using
the X² test. A low P value (or a large X² statistic relative to its
degree of freedom) potentially provides evidence of heterogeneity
of intervention effects and shows that results are not influenced by
chance alone (Higgins 2011). We used the I² statistic to assess the
impact of the heterogeneity on the meta-analysis and interpreted
an I² statistic > 50% as marked heterogeneity (Higgins 2011).
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Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, we aimed to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert to duplication of data. In the presence of
10 or more studies in an analysis, we used a funnel plot to explore
the possibility of small study effects. This was to guide whether
the difference was due to publication or reporting bias. We were
aware that there are other sources of asymmetry in funnel plots
(Stuck 1998).
Data synthesis
The various comparison groups were as follows:
1. any long protocol versus any short protocol;
2. any long protocol versus ultrashort protocol;
3. any short protocol versus ultrashort protocol;
4. long luteal protocol versus long follicular phase protocol;
5. long protocol: continuation versus discontinuation of the
GnRHa at start of stimulation;
6. long protocol: continuation of same-dose GnRHa versus
reduced-dose GnRHa until HCG administration;
7. long protocol: discontinuing versus continuing GnRHa
after HCG administration;
8. long protocol: administration of GnRHa for two versus
three weeks before stimulation; and
9. short protocol: continuation of GnRHa versus stopping
GnRHa.
We performed analysis using RevMan 5.3 software (RevMan
2014). For binary (or dichotomous) outcomes, we expressed the
results for each study as odds ratios (OR) with 95% confidence
intervals (CI) and combined them for meta-analysis, where ap-
propriate. For continuous outcome data, we expressed the results
from each study as a difference in means with 95% CI and com-
bined for meta-analysis using the mean difference (MD).
An increase in the odds of a particular outcome, which may be
beneficial (e.g., live birth) or detrimental (e.g., adverse effects),
are displayed graphically in the meta-analyses to the right of the
centre-line and a decrease in the odds of an outcome to the left of
the centre-line.
Subgroup analysis and investigation of heterogeneity
Where data were available, we planned to conduct subgroup anal-
yses to determine the separate evidence within the following sub-
groups: normal or poor responders, number of embryos trans-
ferred, previous failed cycles, maternal age, and duration of treat-
ment. In cases of substantial heterogeneity, our aim was to explore
possible explanations in sensitivity analyses. We took any statisti-
cal heterogeneity into account when interpreting the results, espe-
cially if there was any variation in the direction of effect. We used
a fixed-effect model.
Sensitivity analysis
We performed sensitivity analysis for the primary outcomes to
determine whether the conclusions were robust to arbitrary deci-
sions made regarding the eligibility and analysis. These analyses
included consideration of whether the review conclusions would
have differed in the following ways:
1. if we had restricted eligibility to studies without high risk of
bias (e.g., clear description of sequence generation and allocation
concealment methods);
2. if we had adopted a random-effects model;
3. if we had implemented alternative imputation strategies; or
4. if the summary effect measure we had used was relative risk
rather than odds ratio.
We did so by excluding studies with unclear randomisation and
studies with incomplete data. There were not enough studies to
support meta-regression or other formal considerations of prog-
nostic factors.
Overall quality of the body of evidence: ’Summary of
findings’ tables
We prepared ’Summary of findings’ tables using GRADEprofiler
(GRADEpro). These tables evaluate the overall quality of the body
of evidence for the main review outcomes (live birth and clinical
pregnancy) using GRADE criteria (study limitations (i.e., risk of
bias), consistency of effect, imprecision, indirectness, and publi-
cation bias). We justify our judgements about evidence quality
(high, moderate, or low) and have documented and incorporated
these into the reporting of results for each outcome.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies, Characteristics of ongoing studies, and the ’Preferred
Reporting Items for Systematic Reviews and Meta-Analyses’
(PRISMA) flowchart (Figure 1).
Results of the search
After searching the electronic databases, we found a total of 2503
studies: 641 in the CochraneMenstrual Disorders and Subfertility
Group Specialised Register, 722 in the Cochrane Central Register
of Controlled Trials (CENTRAL) in the Cochrane Library, 485
in MEDLINE, 369 in EMBASE, 266 in CINAHL (Cumulative
Index to Nursing and Allied Health Literature), and 20 studies
in PsycINFO. After removing the duplicates and searching other
resources, there were approximately 1700 studies left. Of these,
100 seemed eligible for inclusion, and after reading the full text
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articles, we were able to include 37 studies in the review (eight
more than was in the last update). Of note, we considered one
study as two different comparisons (De Placido 1991), which were
present in the study. One study is ongoing (NCT01006954).
We sent two e-mails to trial authors (with a reminder); we received
responses from nine out of 15 study authors (Chatillon-Boissier
2012; Corson 1992; Isikoglu 2007; Lin 2013; NCT00436319;
Sarhan 2013; Sunkara 2014; Tanaka 2014; Tarin 1990).
Included studies
Design
We included 37 studies (3872 women). All were parallel group
randomised controlled trials (RCTs). There were nine different
comparison groups.
1. Long versus short protocol
Twenty studies featured this comparison. An a priori power calcu-
lation was a feature in one study (Sunkara 2014). Weissman 2003
did a power calculation for pregnancy as the outcome but de-
cided to proceed with number of oocytes as the primary outcome
measure because of the large sample size required for determining
a significant difference in the pregnancy rate. Only nine studies
out of 20 reported adequate randomisation (Chatillon-Boissier
2012; Dirnfeld 1991; Fenichel 1988; Foulot 1988; Hazout 1993;
Sunkara 2014; Tan 1992; Weissman 2003; Ye 2001). Three stud-
ies, Chatillon-Boissier 2012; Sunkara 2014; Tan 1992, reported
concealed allocation. The funnel plot did not suggest any publi-
cation bias (Figure 4).
Figure 4. Funnel plot of comparison: 1 Long versus short protocol, outcome: 1.2 Clinical pregnancies.
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2. Long versus ultrashort protocol
Two studies featured this comparison. Of the two (Chen 1992;
Kingsland 1992), the former reported adequate randomisation
and concealed allocation. An a priori power calculation was not a
feature of any study.
3. Short versus ultrashort protocol
One study featured this comparison (Berker 2010): the paper de-
scribed an a priori power calculation, randomisation, and alloca-
tion concealment.
4. Long protocol: luteal versus follicular start of
gonadotrophin-releasing hormone agonists (GnRHa)
Five studies featured this comparison. Of them, only Kondaveeti-
Gordon 1996 had an a priori power calculation. Kondaveeti-
Gordon 1996; Urbancsek 1996; and Sarhan 2013 reported
clear randomisation and concealment. Although blinding un-
til objective outcome assessment was planned for one study
(Kondaveeti-Gordon 1996), it was revealed after the study was
started. Urbancsek 1996 reported more than one cycle per partic-
ipant.
5. Long protocol: continuation of GnRHa versus stopping
GnRHa at start of stimulation
Three studies featured this comparison (Dirnfeld 1999; Garcia-
Velasco 2000; Simons 2005). Of them, only one was double
blinded (Simons 2005). All of the three studies reported adequate
randomisation and concealment.
6. Long protocol: continuation of same-dose GnRHa versus
reduced-dose GnRHa until HCG administration
Four studies featured this comparison. All of them reported ad-
equate randomisation, while three reported concealed allocation
(Dal Prato 2001; Ding 2013; Fábregues 2005).
7. Long protocol: discontinuing versus continuing GnRHa
after HCG administration
One study featured this comparison (Isikoglu 2007). The study re-
ported adequate randomisation (computer-generated list), blind-
ing, and concealment, but there was no power calculation.
8. Long protocol: administration of GnRHa for two versus
three weeks before stimulation
One study featured this comparison (Lin 2013). The study
reported adequate randomisation (computer-generated random
numbers two weeks after GnRHa administration), but there was
no concealment or blinding.
9. Short protocol: continuation versus stopping GnRHa
One study featured this comparison (Cedrin-Durnerin 2000). The
study reported adequate randomisation, but there was no conceal-
ment or blinding.
Participants
1. Long versus short protocol
Inclusion criteria for included studies varied widely. Some studies
included women with all causes of infertility, Acharya 1992; Tan
1992; Tasdemir 1995, while others restricted inclusion to women
with only tubal factor infertility, Fenichel 1988; Frydman 1988;
Loumaye 1989; van de-Helder 1990; Zhang 2009, or tubal and
unexplained infertility (Hazout 1993; Hedon 1988). Some studies
excluded women with polycystic ovary syndrome (PCOS) (Foulot
1988; Yang 1996).
The age of the women included was variable in the different stud-
ies. Some included only women under 38 years (Fenichel 1988;
Hazout 1993; Zhang 2009); others included women up until the
age of 40 years (Chatillon-Boissier 2012; Loumaye 1989; Sunkara
2014; van de-Helder 1990).
Some studies included women undergoing only the first in vitro
fertilisation (IVF) cycle, San Roman 1992; Tasdemir 1995, while
others included all IVF cycles (Hazout 1993). Some included
only previous low or poor responders, Chatillon-Boissier 2012;
Dirnfeld 1991; Sunkara 2014;Weissman 2003, whereas others ex-
cluded previous poor responders (Frydman 1988; van de-Helder
1990).
2. Long versus ultrashort protocol
Couples with all causes of infertility were included in both studies.
Kingsland 1992 only included women with the first cycle.
3. Short versus ultrashort protocol
A total of 82 poor responder participants who underwent intracy-
toplasmic sperm injection (ICSI) were included in this compari-
son. Criteria included at least one of the following: day 3 serum
follicle-stimulating hormone (FSH) level > 10 mIU/mL, < 6 to-
tal antral follicles, prior cycle cancellation, prior poor response
to controlled ovarian hyperstimulation (COH) (either peak E2 <
500 pg/mL, < 6 oocytes retrieved, or both), and aged > 41 (Berker
2010).
4. Long protocol: luteal versus follicular start of GnRHa
Ron-El 1990 included consecutive women whereas Pellicer 1989
included women with normal ovarian function; Urbancsek 1996
included women with tubal and unexplained infertility, and
Sarhan 2013 included women with all types of infertility.
5. Long protocol: continuation of GnRHa versus stopping
GnRHa at start of stimulation
Dirnfeld 1999 excluded women with irregular cycles, and Simons
2005 excludedwomenwith PCOSor poor ovarian reserve. Simons
2005 included only womenunder 39 years of age whereasDirnfeld
1999 included women up to the age of 42 years. Garcia-Velasco
2000 had no exclusion criteria for age.
Dirnfeld 1999 included onlywomenwith a previous poor response
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or high FSH; some studies included only previous low responders
(Garcia-Velasco 2000; Simons 2005).
6. Long protocol: continuation of same-dose GnRHa versus
reduced-dose GnRHa until HCG administration
Inclusion criteria for the included studies varied widely. One,
Simon 1994, restricted inclusion to only tubal factor infertil-
ity while another included tubal and unexplained infertility (Dal
Prato 2001). Dal Prato 2001 excluded women with a risk of hy-
perstimulation or with poor ovarian reserve while Ding 2013 in-
cluded women with high response to gonadotrophin stimulation,
that is, “women with eight or more subcapsular follicles of 2 to
8 mm in diameter in one plane in either ovary”. The age of the
women included was variable in the different studies: under 35
(Ding 2013), 38 (Dal Prato 2001), and under 39 years (Simon
1994). Fábregues 2005 and Ding 2013 included women under-
going their first IVF cycle.
7. Long protocol: discontinuing versus continuing GnRHa
after HCG administration
One hundred eighty-one women undergoing 181 consecutive
ICSI cycles were included, with a mean age of 30 years.
8. Long protocol: administration of GnRHa for two versus
three weeks before stimulation
One hundred participants undergoing IVF/ICSI cycle were in-
cluded, with a mean age of 29 years. Inclusion criteria: (a) sub-
fertile participants undergoing first IVF/(ICSI) with tubal factor,
male factor, or unexplained factor; (b) undertaking a luteal long
protocol; (c) basal FSH levels 10 IU/L; and (d) aged 35 years. Ex-
clusion criteria: (a) endometriosis, (b) adenomyosis, and (c) poly-
cystic ovarian syndrome.
9. Short protocol: continuation versus stopping GnRHa
Cedrin-Durnerin 2000 excluded women older than 43 years and
those with anovulation.
Interventions
1. Long versus short protocol
Twenty trials compared a long protocol with a short protocol. In
six studies, Acharya 1992; Foulot 1988; Frydman 1988; Hazout
1993; Hedon 1988; Tan 1992, GnRHa was commenced in the
follicular phase whereas it was commenced in the luteal phase in
the rest of the studies (Chatillon-Boissier 2012; De Placido 1991;
Fenichel 1988; Loumaye 1989; San Roman 1992; Sunkara 2014;
Tasdemir 1995; van de-Helder 1990; Weissman 2003; Ye 2001;
Zhang 2009). In two studies, Dirnfeld 1991; Yang 1996, it was
not clear whether a follicular or luteal start was used.
There was a wide variation in the dose, type, and route of GnRHa
used for down-regulation in long protocols. Buserelin was used
either by nasal spray or subcutaneous injections: 1000 µg twice
a day (Dirnfeld 1991); 200 µg five times a day (Acharya 1992);
900 µg/day (Loumaye 1989; Tasdemir 1995; Ye 2001); 300 µg
twice a day (De Placido 1991; Frydman 1988; Hedon 1988); 200
µg three times daily (van de-Helder 1990); 0.3 ml daily (Foulot
1988); 200 µg daily (Tan 1992); and 100 µg/day (Weissman
2003). Decapeptyl was used either as a short-acting (100 µg/day)
(Cedrin-Durnerin 2000; Chatillon-Boissier 2012) or long-acting
single intramuscular injection (3.75 mg) (Fenichel 1988) or 1.88
mg of intramuscular Diphereline® (Zhang 2009). Other studies
used leuprolide acetate (1mg/day) (San Roman 1992; Yang 1996).
Hazout 1993 repeated the decapeptyl injection twice, which may
explain amuch higher requirement of gonadotrophins. One study,
Sunkara 2014, used nafarelin nasal spray 400 mg twice daily.
In studies comparing a long protocol versus a short protocol, Gn-
RHa was continued at the same dose until HCG administra-
tion except in five studies that reduced the dose at confirmation
of down-regulation: reduced from 1000 µg to 600 µg (Dirnfeld
1991), reduced from 1 mg to 0.5 mg/day (San Roman 1992),
while Weissman 2003 and Chatillon-Boissier 2012 halved the ag-
onist dose, and Sunkara 2014 continued with a reduced dose of
nafarelin 200 mg twice daily until the administration of HCG
injection.
Similarly, the dose ofGnRHa for short protocols varied.Weissman
2003 applied a modified short protocol using the flare effect ini-
tially (500 µg/day for the initial four days followed by 100 µg
until the day of HCG). Yang 1996 used another modification of
the short protocol where GnRHa was stopped after seven days.
Dose, regimen, and drugs used for stimulation also varied in all
studies as did the inclusion criteria of the population studied
(please see the ’Characteristics of included studies’ tables).
2. Long versus ultrashort protocol
Of the two studies included in this comparison, Kingsland 1992
used 200 µg daily of buserelin whereas Chen 1992 used 1 mg daily
of subcutaneous decapeptyl for the long protocol. Both studies
discontinued GnRHa after confirmation of down-regulation.
The dose of GnRHa for the ultrashort protocol was different
as well. Chen 1992 used leuprolide acetate 1 mg daily whereas
Kingsland 1992 used 500 µg/day of buserelin on days two, three,
and four of the cycle.
Chen 1992 used follicle-stimulating hormone (FSH) + hu-
man menopausal gonadotrophin (HMG) for stimulation whereas
Kingsland 1992 used HMG alone
3. Short versus ultrashort protocol
Participants were randomised into two groups.
1. The participants in the ultrashort gonadotrophin-releasing
hormone (GnRH) agonist/GnRH antagonist group (n = 41)
were administered leuprolide acetate at 40 microg
subcutaneously/twice daily, started on day two of menses and
continued for three consecutive days, followed by
gonadotrophins, and GnRH antagonist cetrorelix at 0.25 mg/
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day when the leading follicle was more than 14 mm, which was
continued up to HCG injection.
2. The participants in the microdose group (n = 41) started to
use leuprolide acetate at 40 microg subcutaneously/twice daily
on day two of menses, and two days after initiation of GnRHa,
gonadotropin stimulation was initiated and continued until
HCG day.
The starting dose of recombinant FSH depended on age, body
mass index (BMI), and ovarian response to the previous cycle and
increased to a maximum of 450 IU/day depending on the ovarian
response; it was then individualised after day five (Berker 2010).
4. Long protocol: luteal versus follicular start of GnRHa
Three studies out of five included in this comparison used
the same dose of GnRHa for down-regulation (1200 µg/day),
Kondaveeti-Gordon 1996; Urbancsek 1996, and 0.1 mg of trip-
torelin subcutaneously daily (Sarhan 2013). Ron-El 1990 used a
long-acting preparation (3.2mg decapeptyl) whereas Pellicer 1989
used 600 µg/day buserelin in two divided doses. In Pellicer 1989,
the day for luteal start varied, ranging from four to 10 days after
ovulation compared with the day 21 to 22 start in the other in-
cluded studies. Thismight have had some impact on the outcomes
of the luteal phase results. Urbancsek 1996 considered more than
one cycle per woman whereas the remaining four studies evaluated
only the first cycle. All studies except Pellicer 1989 and Sarhan
2013 used HMG for ovarian stimulation; the former used HMG
+ FSH, and the latter administered either HMG or FSH.
5. Long protocol: continuation of GnRHa versus stopping
GnRHa at start of stimulation
Of the three studies included in this comparison, one used busere-
lin (1000 µg/day) (Dirnfeld 1999), one used leuprolide acetate (1
mg/day) (Garcia-Velasco 2000), and the third used triptorelin (0.1
mg/day) (Simons 2005) for down-regulation. All of the studies
stopped GnRHa at confirmation of down-regulation in the test
arm.
Apart from one study (Garcia-Velasco 2000), which used FSH +
HMG, all used HMG alone for stimulation.
6. Long protocol: continuation of same-dose GnRHa versus
reduced-dose GnRHa until HCG administration
For the four studies in this comparison, there was a variation in the
type and dose of GnRHa and the reduction in dose after down-
regulationwas confirmed: luteinising hormone-releasinghormone
agonist (LHRHa) commenced at 0.5 mg/day and reduced to 0.1
mg/day (Simon 1994); triptorelin acetate commenced at 0.1 mg/
day and reduced to 0.05 mg/day (Fábregues 2005); GnRHa com-
menced at 100 µg/day and reduced to 50 µg/day (Dal Prato
2001); and triptorelin was initiated during the luteal phase, 0.1
mg/day for 10 days followed by 0.05 mg/day until the concentra-
tion of serum oestradiol was </= 40 pg/ml, then the stimulation of
the ovaries started and when the diameter of one or more follicles
was 14 mm, triptorelin (0.05 mg/day) was withdrawn for two (15/
47) or three (32/47) days (Ding 2013).
The stimulation drug varied amongst the studies. Simon 1994
used HMG, Fábregues 2005 and Ding 2013 used recombinant
FSH, while Dal Prato 2001 used metrodin.
7. Long protocol: discontinuing versus continuing GnRHa
after HCG administration
GnRHa was administered from the 21st day of the preceding cy-
cle. Participants were divided into two groups: (1) (n = 90 partic-
ipants) participants were continuously administered GnRHa for
12 days after embryo transfer; (2) (n = 91 participants) GnRHa
was stopped on the day of HCG administration.
8. Long protocol: administration of GnRHa for two versus
three weeks before stimulation
In both groups, a single dose of long-acting GnRHa (Diphere-
line®, 1.25 mg) was administered in the mid-luteal phase. Partic-
ipants were divided into two groups according to the initiation of
gonadotrophins (14 or 21 days after GnRHa administration). Ei-
ther recombinant follicle-stimulating hormone (rFSH) or HMG
was used for ovarian stimulation.
9. Short protocol: continuation versus stopping GnRHa
There was only one study in this comparison. A short protocol
was comparedwith stoppingGnRHahalfway through stimulation
rather than continuing until the day of HCG.
Outcomes
Nineteen studies reported either live birth rate or ongoing preg-
nancy rate (Acharya 1992; Chatillon-Boissier 2012; Ding 2013;
Dirnfeld 1991; Dirnfeld 1999; Foulot 1988; Frydman 1988;
Isikoglu 2007; Kingsland 1992; Lin 2013; Loumaye 1989; San
Roman 1992; Simons 2005; Sunkara 2014; Urbancsek 1996;
van de-Helder 1990; Yang 1996; Ye 2001; Zhang 2009). With
regard to adverse outcomes, 22 studies reported cycle can-
cellation rate (Acharya 1992; Berker 2010; Cedrin-Durnerin
2000; Chatillon-Boissier 2012; Dal Prato 2001; Ding 2013;
Dirnfeld 1991; Dirnfeld 1999; Foulot 1988; Frydman 1988;
Garcia-Velasco 2000; Hazout 1993; Isikoglu 2007; Kingsland
1992; Kondaveeti-Gordon 1996; San Roman 1992; Sarhan 2013;
Simons 2005; Sunkara 2014; van de-Helder 1990; Weissman
2003; Zhang 2009), while two trials reported ovarian hyperstim-
ulation syndrome (OHSS), Ding 2013; Lin 2013, and one study
reported miscarriage rate (Lin 2013).
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1. Long versus short protocol
The outcomes reported in this comparison group were as fol-
lows: live birth/ongoing pregnancies in 12 studies (Acharya 1992;
Chatillon-Boissier 2012; Dirnfeld 1991; Foulot 1988; Frydman
1988; Loumaye 1989; San Roman 1992; Sunkara 2014; van
de-Helder 1990; Yang 1996; Ye 2001; Zhang 2009), clinical preg-
nancies in 19 studies (Acharya 1992; Chatillon-Boissier 2012;
De Placido 1991; Dirnfeld 1991; Fenichel 1988; Foulot 1988;
Frydman 1988; Hazout 1993; Hedon 1988; Loumaye 1989; San
Roman 1992; Sunkara 2014; Tan 1992; Tasdemir 1995; van
de-Helder 1990; Weissman 2003; Yang 1996; Ye 2001; Zhang
2009), number of oocytes in 10 studies (Chatillon-Boissier 2012;
Dirnfeld 1991; Hazout 1993; Loumaye 1989; San Roman 1992;
Sunkara 2014; Weissman 2003; Yang 1996; Ye 2001; Zhang
2009), dose of gonadotrophins in eight studies (Chatillon-Boissier
2012; Dirnfeld 1991; Hazout 1993; Sunkara 2014; Weissman
2003; Yang 1996; Ye 2001; Zhang 2009), cycle cancellation
in 11 studies (Acharya 1992; Chatillon-Boissier 2012; Dirnfeld
1991; Foulot 1988; Frydman 1988; Hazout 1993; San Roman
1992; Sunkara 2014; vande-Helder 1990;Weissman 2003;Zhang
2009), and other outcomes in none of the included studies.
2. Long versus ultrashort protocol
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies in one study (Kingsland 1992),
clinical pregnancies in two studies (Chen 1992; Kingsland 1992),
number of oocytes in two studies (Chen 1992; Kingsland 1992),
dose of gonadotrophins in one study (Chen 1992), cycle cancella-
tion in one study (Kingsland 1992), and other outcomes in none
of the included studies.
3. Short versus ultrashort protocol
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies in none of the included studies,
clinical pregnancies in one study (Berker 2010), number of oocytes
in one study (Berker 2010), dose of gonadotrophins in one study
(Berker 2010), cycle cancellation in one study (Berker 2010), and
other outcomes in none of the included studies.
4. Long protocol: luteal versus follicular start of GnRHa
The outcomes reported in this comparison group were as fol-
lows: live birth/ongoing pregnancies in one study (Urbancsek
1996), clinical pregnancies in five studies (Kondaveeti-Gordon
1996; Pellicer 1989; Ron-El 1990; Sarhan 2013; Urbancsek
1996), number of oocytes in four studies (Kondaveeti-Gordon
1996; Pellicer 1989; Ron-El 1990; Sarhan 2013), dose of go-
nadotrophins in four studies (Kondaveeti-Gordon 1996; Pellicer
1989; Ron-El 1990; Sarhan 2013), cycle cancellation in two stud-
ies (Kondaveeti-Gordon 1996; Sarhan 2013), and other outcomes
in none of the included studies.
5. Long protocol: continuation of GnRHa versus stopping
GnRHa at start of stimulation
The outcomes reported in this comparison group were as fol-
lows: live birth/ongoing pregnancies in three studies (Ding 2013;
Dirnfeld 1999; Simons 2005), clinical pregnancies in four studies
(Ding 2013; Dirnfeld 1999; Garcia-Velasco 2000; Simons 2005),
number of oocytes in four studies (Ding 2013; Dirnfeld 1999;
Garcia-Velasco 2000; Simons 2005), dose of gonadotrophins in
four studies (Ding 2013; Dirnfeld 1999; Garcia-Velasco 2000;
Simons 2005), cycle cancellation in three studies (Dirnfeld 1999;
Garcia-Velasco 2000; Simons 2005), and other outcomes (OHSS)
in one study (Ding 2013).
6. Long protocol: continuation of same-dose GnRHa versus
reduced-dose GnRHa until HCG administration
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies in none of the included studies,
clinical pregnancies in four studies (Dal Prato 2001; Ding 2013;
Fábregues 2005; Simon 1994), number of oocytes in three studies (
Ding 2013; Fábregues 2005; Simon 1994) dose of gonadotrophins
in two studies (Dal Prato 2001; Ding 2013), cycle cancellation in
two studies (Dal Prato 2001; Ding 2013), and other outcomes in
none of the included studies.
7. Long protocol: discontinuing versus continuing GnRHa
after HCG administration
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies in one study (Isikoglu 2007), clin-
ical pregnancies in one study (Isikoglu 2007), number of oocytes
in one study (Isikoglu 2007), dose of gonadotrophins in one study
(Isikoglu 2007), cycle cancellation in one study (Isikoglu 2007),
and other outcomes in none of the included studies.
8. Long protocol: administration of GnRHa for two versus
three weeks before stimulation
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies in one study (Lin 2013), clinical
pregnancies in one study (Lin 2013), number of oocytes in one
study (Lin 2013) and dose of gonadotrophins in one study (Lin
2013). None of the included studies reported cycle cancellation
or other outcomes of interest.
9. Short protocol: continuation versus stopping GnRHa
The outcomes reported in this comparison group were as follows:
live birth/ongoing pregnancies rate in none of the included stud-
ies, clinical pregnancies in one study (Cedrin-Durnerin 2000),
number of oocytes in none of the included studies, dose of go-
nadotrophins in one study (Cedrin-Durnerin 2000), cycle cancel-
lation in one study (Cedrin-Durnerin 2000), and other outcomes
in none of the included studies.
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For the characteristics of included studies, see the ’Characteristics
of included studies’ tables.
Excluded studies
A list of the 63 excluded studies is provided in a table, along with
the reasons for exclusion (please see the ’Characteristics of excluded
studies’ tables).
Risk of bias in included studies
A complete overview of our classification of risk of bias domains
can be found in the ’Characteristics of included studies’ tables. The
following is a summary ofmethods, participants, and interventions
in the included studies for the various comparisons. See Figure 2
and Figure 3.
Allocation
Random sequence generation
Adequate sequence generationwas present in 22out of 37 included
studies, which we considered as at low risk of selection bias. For the
remaining 15 studies, there was no clear mention of the method
of randomisation (Acharya 1992; Chen 1992; De Placido 1991;
Dirnfeld 1999; Frydman 1988; Hedon 1988; Loumaye 1989;
Pellicer 1989; Ron-El 1990; San Roman 1992; Tasdemir 1995;
Urbancsek 1996; van de-Helder 1990; Yang 1996; Zhang 2009),
so we judged them to be at unclear risk of bias. We rated 22 studies
as low risk of this bias, no studies as high risk, and 16 studies as at
unclear risk.
Allocation concealment
Eight studies used adequate methods for concealment of the ran-
dom sequence, using sealed envelopes, andwe judged these to be at
low risk of selectionbias (Berker 2010;Dal Prato 2001;Ding 2013;
Fábregues 2005; Kingsland 1992; Simons 2005; Sunkara 2014;
Tan 1992). Twenty-three studies did not report an attempt to con-
ceal the allocation; we judged these to be at unclear risk of bias. We
rated six studies as high risk as the authors reported no conceal-
ment of allocation (Dirnfeld 1991; Fenichel 1988; Hazout 1993;
Kondaveeti-Gordon 1996; San Roman 1992; Ye 2001) (Figure 2;
Figure 3).
Blinding
Although our outcomes of interest were objective, we believe that
blinding of clinicians and participants is important in order to
avoid performance and detection biases. Blinding the clinician or
participants was not a feature in 26 studies included in the review.
We judged only two studies as low risk (Simons 2005; Sunkara
2014). We rated nine studies as “unclear” concerning risk of bias,
as there were no data regarding blinding (Berker 2010; Dal Prato
2001; De Placido 1991; Ding 2013; Foulot 1988; Garcia-Velasco
2000; Sarhan 2013; Yang 1996; Zhang 2009).
We rated two studies as at low risk of bias, 26 studies as at high
risk, and nine studies as at unclear risk regarding blinding.
Incomplete outcome data
We rated eight out of 37 studies as at high risk of attrition bias (
Ding 2013;Dirnfeld 1999; Fábregues 2005;Hazout 1993;Hedon
1988; Simon 1994; Tasdemir 1995; Urbancsek 1996), four out
of 37 studies as at unclear risk of attrition bias (Chen 1992; De
Placido 1991; Kondaveeti-Gordon 1996; Pellicer 1989), and the
rest of them as at low risk of attrition bias (Acharya 1992; Berker
2010; Cedrin-Durnerin 2000; Chatillon-Boissier 2012; Dal Prato
2001;Dirnfeld 1991; Fenichel 1988; Foulot 1988; Frydman 1988;
Garcia-Velasco 2000; Isikoglu 2007; Kingsland 1992; Lin 2013;
Loumaye 1989; San Roman 1992; Sarhan 2013; Simons 2005;
Sunkara 2014; Tan 1992; van de-Helder 1990; Weissman 2003;
Yang 1996; Ye 2001; Zhang 2009).
We rated 25 studies as at low risk of attrition bias, five studies as
at unclear risk, and eight studies as at high risk.
Selective reporting
Eighteen studies reported at least one of the twoprimary outcomes:
live birth or ongoing pregnancy rate. We judged these to be at
low risk of reporting bias (Berker 2010; Chatillon-Boissier 2012;
Ding 2013; Dirnfeld 1991; Foulot 1988; Frydman 1988; Hedon
1988; Isikoglu 2007; Kingsland 1992; Lin 2013; Loumaye 1989;
San Roman 1992; Simons 2005; Sunkara 2014; Tasdemir 1995;
Urbancsek 1996; van de-Helder 1990;Weissman 2003). Eighteen
trials failed to report either of the two primary outcomes for this
review, sowe judged these to be at unclear risk of reporting bias.We
judged one trial to be at high risk because it reported only clinical
pregnancy, without reporting any other outcomes (De Placido
1991).
We rated 18 studies as at low risk of bias, one study as at high risk,
and 18 studies as at unclear risk regarding selective reporting.
Other potential sources of bias
In the majority of included studies (23 studies), there was insuf-
ficient information to assess whether an important risk of bias
existed. We judged five trials as high risk for different reasons
(Cedrin-Durnerin 2000;De Placido 1991;Dirnfeld 1991; Pellicer
1989; Tasdemir 1995). In one trial, the median number of em-
bryos transferred was significantly different between the interven-
tion and the control group. Besides, there was no mention of the
exact number of participants in each group (Tasdemir 1995). In
one study, the intervention and the control group commenced
GnRHa on different days (Pellicer 1989). In one study, the long
GnRH protocol was commenced in either the luteal or follicular
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phase (Dirnfeld 1991). In two trials, data regarding the number of
participants and other inclusion criteria were lacking (De Placido
1991). One trial excluded an important group of IVF participants
(participants with chronic anovulation) from participation and
used two variants of short protocol (Cedrin-Durnerin 2000). We
judged the rest of the trials (nine trials) as at low risk for other
potential sources of bias.
We rated nine studies as at low risk of bias, five studies as at high
risk, and 23 studies as at unclear risk in this domain.
Effects of interventions
See: Summary of findings for the main comparison Long
protocol compared with short protocol for pituitary suppression
in assisted reproduction; Summary of findings 2 Long protocol
compared with ultrashort protocol for pituitary suppression in
assisted reproduction; Summary of findings 3 Short compared
with ultrashort protocol for pituitary suppression in assisted
reproduction; Summary of findings 4 Long luteal phase protocol
compared with long follicular phase protocol for pituitary
suppression in assisted reproduction; Summary of findings 5
Long protocol continued GnRH agonist compared with long
protocol stop GnRH agonist for pituitary suppression in assisted
reproduction; Summary of findings 6 Long protocol (continued
same versus reduced dose GnRHa) for pituitary suppression in
assisted reproduction; Summary of findings 7 Long protocol
(GnRHa until HCG) compared with long protocol (extend
GnRHa 12 days after HCG) for pituitary suppression in
assisted reproduction; Summary of findings 8 Long protocol:
administration of GnRHa for two versus three weeks before
stimulation for pituitary suppression in assisted reproduction;
Summary of findings 9 Short protocol compared with stop short
protocol for pituitary suppression in assisted reproduction
1. Long versus short protocol
We included 20 studies in this comparison (Summary of findings
for the main comparison).
Primary outcome measure
1.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in live birth and ongoing
pregnancy rates between the two protocols (odds ratio (OR) 1.30,
95% confidence interval (CI) 0.94 to 1.81; 12 RCTs, n = 976
women, I² = 15%, low quality evidence) (Analysis 1.1; Figure 5;
Summary of findings for the main comparison). Analyses 1.1.1
and 1.1.2 present separately the differences in live and ongoing
pregnancy rates. A sensitivity analysis including only studies with
adequate randomisation and complete outcome data reporting
included five studies (Chatillon-Boissier 2012; Dirnfeld 1991;
Foulot 1988; Sunkara 2014; Ye 2001): there was no evidence of a
difference in live birth and ongoing pregnancy rates between the
two protocols (OR 1.45, 95% CI 0.83 to 2.52; five RCTs, n =
481 women, I² = 0%, moderate quality evidence).
Figure 5. Forest plot of comparison: 1 Long versus short protocol, outcome: 1.1 Live birth/ongoing
pregnancies.
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Secondary outcomes
1.2 Clinical pregnancy rate
There was evidence of an increase in clinical pregnancy rate (OR
1.50, 95% CI 1.18 to 1.92; 20 RCTs, n = 1643 women, I² =
27%, moderate quality evidence) in the long protocol group when
compared with the short protocol group (Analysis 1.2; Figure
6). The subgroup of studies including poor responders only also
showed a difference in clinical pregnancy rates (OR 3.12, 95%
CI 1.39 to 7.02; four RCTs, n = 232 women, I² = 0%, moderate
quality evidence), favouring the longprotocol (Analysis 1.2; Figure
6).
Figure 6. Forest plot of comparison: 1 Long versus short protocol, outcome: 1.2 Clinical pregnancies.
1.3 Number of oocytes
Due to the high heterogeneity of the pooled analysis (10 RCTs, n
= 789 women, I² = 91%), we did not pool data. The heterogeneity
was among the six studies of unselected women. Of these studies,
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two showed a significant difference in favour of the long protocol.
Subgroup analysis of the four studies including poor responders
showed evidence of an increase in the number of oocytes in the
long protocol compared with the short protocol (mean difference
(MD) 1.40, 95% CI 0.75 to 2.06; four RCTs, n = 227 women, I²
= 0%, low quality evidence) (Analysis 1.3).
1.4 Number of ampoules of gonadotrophins
Due to the high heterogeneity of the pooled analysis (eight RCTs,
n = 666 women, I² = 94%), we did not pool data. The heterogene-
ity was among the four studies of unselected women. All of these
studies showed a significant difference in favour of the long pro-
tocol. Subgroup analysis of the studies including poor responders
showed evidence of a substantial increase in the requirement of
gonadotrophins in a long protocol compared with a short protocol
(MD 7.07, 95% CI 3.06 to 11.08; four RCTs, n = 227 women,
I² = 0%, low quality evidence) (Analysis 1.4).
1.5 Cycle cancellation rate
There was no evidence of a difference between the groups in the
cycle cancellation rate (OR 0.95, 95% CI 0.59 to 1.55; 11 RCTs,
n = 1026 women, I² = 42%, low quality evidence) (Analysis 1.5).
Subgroup analysis of the four studies including poor responders
showed evidence of fewer cancellations in the long protocol com-
paredwith the short protocol (OR0.31, 95%CI 0.12 to 0.76; four
RCTs, n = 227 women, I² = 0%, low quality evidence) (Analysis
1.5).
1.6 Other outcomes
There were no studies reporting on other adverse outcomes, cost
effectiveness, or acceptability of these drugs.
2. Long versus ultrashort protocol
We included two studies in this comparison (Summary of findings
2).
Primary outcome measure
2.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in live birth and ongoing
pregnancy rates when a long protocol was compared with an ul-
trashort protocol (OR 1.78, 95% CI 0.72 to 4.36; one RCT, n =
150 women, low quality evidence) (Analysis 2.1).
Secondary outcomes
2.2 Clinical pregnancy rate
There was no evidence of a difference in the clinical pregnancy rate
when a long protocol was compared with an ultrashort protocol
(OR 1.56, 95% CI 0.80 to 3.06; two RCTs, n = 230 women, I²
= 67%, low quality evidence) (Analysis 2.2).
2.3 Number of oocytes retrieved
There was no evidence of a difference in the number of oocytes
recovered when a long protocol was compared with an ultrashort
protocol (MD 0.53, 95% CI -0.61 to 1.66; two RCTs, n = 230
women, I² = 67%, low quality evidence) (Analysis 2.3).
2.4 Number of ampoules of gonadotrophins
There was no evidence of a difference in the ampoules of go-
nadotrophins used when a long protocol was compared with an
ultrashort protocol (MD 1.10, 95% CI -1.81 to 4.01; one RCT,
n = 80 women, low quality evidence) (Analysis 2.4).
2.5 Cycle cancellation
There was no evidence of a difference in the cycle cancellation rate
when a long protocol was compared with a short protocol (OR
1.11, 95%CI 0.40 to 3.05; one RCT, n = 150 women, low quality
evidence) (Analysis 2.5).
2.6 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison.
3. Short versus ultrashort protocol
We found only one study for this comparison (Summary of
findings 3).
Primary outcome measure
3.1 Live birth and ongoing pregnancy rates
There were no studies reporting on this outcome.
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Secondary outcome measures
3.2 Clinical pregnancy rate
There was no evidence of a difference in the clinical pregnancy rate
when a short protocol was compared with an ultrashort protocol
(OR 1.33, 95% CI 0.47 to 3.81; one RCT, n = 82 women, very
low quality evidence) (Analysis 3.6).
3.3 Number of oocytes
There was no evidence of a difference in the number of oocytes
recovered when a short protocol was compared with an ultrashort
protocol (MD 0.70, 95% CI -1.83 to 3.23; one RCT, n = 82
women, very low quality evidence) (Analysis 3.7).
3.4 Number of ampoules of gonadotrophins
There was evidence of a difference in the ampoules of go-
nadotrophins used when a short protocol was compared with an
ultrashort protocol (MD -13.85, 95% CI -21.49 to -6.21; one
RCT, n = 82 women, very low quality evidence) (Analysis 3.8).
Fewer ampoules were used in the short protocol group.
3.5 Cycle cancellation
There was no evidence of a difference in the cycle cancellation rate
when a short protocol was used when compared with an ultrashort
(OR 1.00, 95% CI 0.13 to 7.46; one RCT, n = 82 women, very
low quality evidence) (Analysis 3.9).
3.6 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison.
4. Long lutealversus long follicular phase protocol
We included five studies in this comparison (Summary of findings
4).
Primary outcome measure
4.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in live birth and ongoing
pregnancy rates when GnRHa was commenced in the luteal or
follicular phase for the long protocol (OR 1.89, 95% CI 0.87 to
4.10; one RCT, n = 223 women, low quality evidence) (Analysis
4.1).
Secondary outcome measures
4.2 Clinical pregnancy rate
There was no evidence of a difference in the pregnancy rate in
the luteal start of GnRHa when compared with the follicular start
(OR 1.06, 95% CI 0.76 to 1.47; five RCTs, n = 750 women, I² =
52%, low quality evidence) (Analysis 4.2).
4.3 Number of oocytes retrieved
There was no evidence of a difference between the groups in the
number of oocytes retrieved (MD -1.29, 95% CI -1.85 to 0.71;
four RCTS, n = 527 women, I² = 74%, low quality evidence)
(Analysis 4.3).
4.4 Number of ampoules of gonadotrophins
There was no evidence of a difference in the amounts of go-
nadotrophins required in luteal start when compared with follicu-
lar start in long protocols (MD 1.12, 95% CI -0.73 to 2.97; four
RCTs, n = 527 women, I² = 51%, low quality evidence) (Analysis
4.4).
4.5 Cycle cancellation
There was no evidence of a difference in cycle cancellation rates
in the luteal or follicular start of GnRHa groups (OR 1.45, 95%
CI 0.35 to 6.01; two RCTs, n = 267 women, I² = 0%, low quality
evidence) (Analysis 4.5).
4.6 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison for the pri-
mary outcome.
5. Long protocol (continue GnRHa versus stop
GnRHa)
We included four studies in this comparison (Summary of findings
5).
Primary outcome measure
5.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in the number of live birth
and ongoing pregnancies when GnRHa was stopped compared
with when it was continued (OR 0.75, 95%CI 0.42 to 1.33; three
RCTs, n = 290 women, I² = 0%, low quality evidence) (Analysis
5.1; Figure 7).
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Figure 7. Forest plot of comparison: 5 Long protocol (continued GnRHa versus stop GnRHa), outcome: 5.1
Live birth and ongoing pregnancies.
Secondary outcomes
5.2 Clinical pregnancies
There was no evidence of a difference in the clinical pregnancy
rate whether GnRHa was continued or stopped (OR 0.85, 95%
CI 0.51 to 1.41; four RCTs, n = 360 women, I² = 0%, low quality
evidence) (Analysis 5.2).
5.3 Number of oocytes
There was no evidence of a difference in the number of oocytes
retrieved whenGnRHawas continued compared with when it was
stopped (MD -0.26, 95% CI -1.29 to 0.78; four RCTs, n = 360
women, I² = 73%, low quality evidence) (Analysis 5.3).
5.4 Number of ampoules of gonadotrophins
There was no evidence of a difference in the amount of go-
nadotrophins required in the two groups (MD -0.14, 95% CI -
2.35 to 2.08; four RCTs, n = 360 women, I² = 65%, low quality
evidence) (Analysis 5.4).
5.5 Cycle cancellation rate
There was no evidence of a difference in the cycle cancellation rate
when GnRHa was stopped compared with when it was continued
(OR 1.47, 95% CI 0.04 to 5.35; three RCTs, n = 264 women, I²
= 69%, low quality evidence) (Analysis 5.5).
5.6 Other outcomes
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison.
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols, apart
from the OHSS rate (Ding 2013).
There was no evidence of a difference in rate of OHSS between
the two groups compared (OR 0.47, 95% CI 0.04 to 5.35; one
RCT, n = 96 women, low quality evidence) (Analysis 5.6).
6. Long protocol (continued same-dose GnRHa
versus reduced-dose GnRHa)
We included four RCTs in this comparison (Summary of findings
6).
Primary outcome measure
6.1 Live birth and ongoing pregnancy rates
No study reported on this outcome.
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6.2 Clinical pregnancy rate
There was no evidence of a difference in the pregnancy rate when
the dose of GnRHa was reduced compared with when the same
dose was continued (OR 1.02, 95% CI 0.68 to1.52; four RCTs,
n = 407 women, I² = 0%, low quality evidence) (Analysis 6.2).
6.3 Number of oocytes
There was no evidence of a difference in the number of oocytes
retrieved between groups (MD 1.03, 95% CI -0.04 to 2.10; three
RCTs, n = 275 women, I² = 0%, low quality evidence) (Analysis
6.3).
6.4 Number of ampoules of gonadotrophins
There was no evidence of a difference in the number of ampoules
of gonadotrophins required between the compared groups (MD
0.98, 95% CI -1.72 to 3.69; two RCTs, n = 228 women, I² =
58%, low quality evidence) (Analysis 6.4).
6.5 Cycle cancellation rate
There was no evidence of a difference in the cycle cancellation rate
for the two groups (OR 1.00, 95% CI 0.14 to 7.32; two RCTs, n
= 228 women, I² = not applicable, low quality evidence) (Analysis
6.5).
6.7 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
Neither sensitivity nor subgroup analysis was done because of the
lack of studies reporting on this comparison and addressing the
primary outcome.
7. Long protocol: discontinuing versus continuing
GnRHa after HCG administration
We included only one study in this comparison (Summary of
findings 7).
Primary outcome measure
7.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in live birth and ongoing
pregnancy rates in this comparison (OR 0.89, 95% CI 0.49 to
1.64; one RCT, n = 181 women, low quality evidence) (Analysis
7.1).
Secondary outcome measures
7.2 Clinical pregnancy rate
There was no evidence of a difference in the clinical pregnancy
rate when discontinuing versus continuing GnRHa after HCG
administration (OR 1.02, 95% CI 0.57 to 1.83; one RCT, n =
181 women, low quality evidence) (Analysis 7.2).
7.3 Number of oocytes retrieved
There was no evidence of a difference between the two compared
groups (MD -0.90, -3.04 to 1.24; one RCT, n = 181 women, low
quality evidence) (Analysis 7.3).
7.4 Number of ampoules of gonadotrophins
There was no evidence of a difference in the requirement for go-
nadotrophins between the two compared groups (MD 2.80, -0.55
to 6.15; one RCT, n = 181 women, low quality evidence) (Analysis
7.4).
7.5 Cycle cancellation
There was no evidence of a difference in the cycle cancellation rate
in either group (OR 1.50, 95% CI 0.24 to 9.20; one RCT, n =
181 women, low quality evidence) (Analysis 7.5).
7.6 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison and address-
ing the primary outcome.
8. Long protocol: administration of GnRHa for two
versus three weeks before stimulation
We included only one study in this comparison (Summary of
findings 8).
Primary outcome measure
8.1 Live birth and ongoing pregnancy rates
There was no evidence of a difference in the live birth and ongoing
pregnancy rates when administration of GnRH lasted for three
or two weeks, respectively, before stimulation (OR 0.88, 95% CI
0.37 to 2.05; one RCT, n = 85 women, low quality evidence)
(Analysis 8.1).
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Secondary outcome measures
8.2 Clinical pregnancy rate
There was no evidence of a difference in the clinical pregnancy
rate when administration of GnRH lasted for three or two weeks,
respectively, before stimulation (OR 0.93, 95% CI 0.39 to 2.21;
one RCT, n = 85 women, low quality evidence) (Analysis 8.2).
8.3 Total number of oocytes retrieved
There was no evidence of a difference between the groups in the
number of oocytes retrieved (MD 12, 95% CI -1.90 to 2.14; one
RCT, n = 85 women, low quality evidence) (Analysis 8.3).
8.4 Total dose of gonadotrophins
There was no evidence of a difference between the groups in the
ampoules of gonadotrophins (MD 207.00, 95% CI -44.65 to
458.65; one RCT, n = 85 women, low quality evidence) (Analysis
8.4).
8.5 Cycle cancellation rate
There was no study reporting on this outcome.
8.6 Other outcomes
Neither sensitivity nor subgroup analysis was done because of the
low number of studies reporting on this comparison and address-
ing the primary outcome.
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols, apart
from OHSS (Lin 2013) and miscarriage rates (Lin 2013).
a. Miscarriage rate
There was no evidence of a difference in miscarriages between the
two groups (OR 0.93, 95% CI 0.18 to 4.87; one RCT, n = 85
women, low quality evidence) (Analysis 8.6)
b. OHSS rate
There was no evidence of a difference in OHSS rate between the
groups (OR0.93, 95%CI 0.06 to 15.37; one RCT, n = 85women,
low quality evidence) (Analysis 8.6).
9. Short versus stop short protocol
We included only one study in this comparison (Summary of
findings 9).
Primary outcome measure
9.1 Live birth and ongoing pregnancy rates
This was not reported for the comparison.
Secondary outcome measures
9.2 Clinical pregnancy rate
There was no evidence of a difference in the clinical pregnancy
rate (OR 0.59, 95% CI 0.30 to 1.17; one RCT, n = 230 women,
low quality evidence) when a short protocol was compared with a
stop short protocol (Analysis 9.2).
9.3 Total number of oocytes retrieved
This was not reported for the comparison.
9.4 Number of ampoules of gonadotrophins
There was evidence of a difference in the requirement for go-
nadotrophins with a short stop protocol requiring fewer ampoules
of gonadotrophins (MD -5.20, -8.11 to -2.29; one RCT, n = 230
women, low quality evidence) (Analysis 9.4).
9.5 Cycle cancellation
There was no evidence of a difference between the groups in the
cycle cancellation rate (OR 0.73, 95% CI 0.34 to 1.59; one RCT,
n = 230 women, low quality evidence) (Analysis 9.5).
9.7 Other outcomes
There were no studies reporting on other adverse effects, cost ef-
fectiveness, and acceptability of either of these protocols.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Long protocol compared with ultrashort protocol for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol
Comparison: ultrashort protocol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Ultrashort protocol Long protocol
Live birth and ongoing
pregnancies
per woman randomised
122 per 1000¹ 198 per 1000
(91 to 376)
OR 1.78
(0.72 to 4.36)
150
(1 study)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
Clinical pregnancies
per woman randomised
161 per 1000 230 per 1000
(133 to 370)
OR 1.56
(0.8 to 3.06)
230
(2 studies)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²High risk of bias associated with poor reporting of methods in the primary study or studies.
³Imprecision: the confidence interval is compatible with benefit in one or both groups or with no effect.
The assumed risk in the control group was determined as the median value across included studies.
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Short protocol compared with ultrashort protocol for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: short protocol
Comparison: ultrashort protocol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Ultrashort protocol Short
Live birth and ongoing
pregnancies
per woman randomised
Not reported in the included study - -
Clinical pregnancies
per woman randomised
195 per 1000¹ 244 per 1000
(102 to 480)
OR 1.33
(0.47 to 3.81)
82
(1 study)
⊕⊕©©
Very low²,³
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²Applicability uncertain: the population is a selected group of participants (poor responders).
³Imprecision: single underpowered trial with a small number of events; the confidence interval is compatible with benefit in either group
or with no effect.
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Long luteal phase protocol compared with long follicular phase protocol for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long luteal phase protocol
Comparison: long follicular phase protocol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long follicular phase
protocol
Long luteal phase proto-
col
Live birth and ongoing
pregnancies
per woman randomised
102 per 1000¹ 177 per 1000
(90 to 319)
OR 1.89
(0.87 to 4.1)
223
(1 study)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
Clinical pregnancies
per woman randomised
269 per 1000 281 per 1000
(219 to 351)
OR 1.06
(0.76 to 1.47)
750
(5 studies)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²High risk of bias associated with poor reporting of methods in the primary study or studies.
³Imprecision: the confidence interval is compatible with benefit in either group or with no effect.
The assumed risk in the control group was determined as the median value across included studies.
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Long protocol continued GnRH agonist compared with long protocol stop GnRH agonist for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol continued GnRH agonist
Comparison: long protocol stop GnRH agonist
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long protocol stop GnRH
agonist
Long protocol continued
GnRH agonist
Live birth and ongoing
pregnancies
Number of live births or
ongoing pregnancies per
woman randomised
276 per 1000¹ 222 per 1000
(138 to 336)
OR 0.75
(0.42 to 1.33)
290
(3 studies)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
Clinical pregnancies
Number of clinical preg-
nancies per woman ran-
domised
235 per 1000¹ 207 per 1000
(135 to 302)
OR 0.85
(0.51 to 1.41)
360
(4 studies)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GnRH: gonadotrophin-releasing hormone; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²High risk of bias associated with poor reporting of methods in one or more of the primary studies.
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³Imprecision: the confidence interval is compatible with benefit in either group or with no effect.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Long protocol (continued same versus reduced dose GnRHa) for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol continued same
Comparison: long protocol reduced dose GnRHa
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long protocol, reduced
dose GnRHa
Long protocol, continued
same
Live birth and ongoing
pregnancies
per woman randomised
No studies reported this outcome - -
Clinical pregnancies
per woman randomised
377 per 1000¹ 382 per 1000
(292 to 479)
OR 1.02
(0.68 to 1.52)
407
(4 studies)
⊕⊕©©
Low²,³
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GnRHa: gonadotrophin-releasing hormone agonists; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as the median value across included studies.
²High risk of bias associated with poor reporting of methods in one or more of the primary studies.
³Imprecision: the confidence interval is compatible with benefit in either group or with no effect.
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Long protocol (GnRHa until HCG) compared with long protocol (extend GnRHa 12 days after HCG) for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol (GnRHa until HCG)
Comparison: long protocol (extend GnRHa 12 days after HCG)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long protocol (extend
GnRHa 12 days after
HCG)
Long protocol (GnRHa
until HCG)
Live birth and ongoing
pregnancies
per woman randomised
378 per 1000¹ 351 per 1000
(229 to 499)
OR 0.89
(0.49 to 1.64)
181
(1 study)
⊕⊕©©
Low²
No evidence of a differ-
ence between the groups
Clinical pregnancies
per woman randomised
489 per 1000¹ 494 per 1000
(353 to 636)
OR 1.02
(0.57 to 1.83)
181
(1 study)
⊕⊕©©
Low²
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GnRHa: gonadotrophin-releasing hormone agonists; HCG: human chorionic gonadotrophin; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²The level of evidence was downgraded by two levels due to imprecision: only one underpowered trial with relatively small number of
events and wide confidence interval compatible with benefit in either group or with no effect.
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long protocol: administration of GnRHa for two versus three weeks before stimulation for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: long protocol: administration of GnRHa for two weeks before stimulation
Comparison: long protocol: administration of GnRHa for three weeks before stimulation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Long protocol: admin-
istration of GnRHa for
three weeks before stim-
ulation
Long protocol: adminis-
tration of GnRHa for two
weeks before stimula-
tion
Live birth and ongoing
pregnancies
per woman randomised
488 per 1000¹ 456 per 1000
(261 to 661)
OR 0.88
(0.37 to 2.05)
85
(1 study)
⊕⊕©©
Low²
No evidence of a differ-
ence between the groups
Clinical pregnancies
per woman randomised
585 per 1000¹ 568 per 1000
(355 to 757)
OR 0.93
(0.39 to 2.21)
85
(1 study)
⊕⊕©©
Low²
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; GnRHa: gonadotrophin-releasing hormone agonists; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²High risk of bias associated with poor reporting of methods in one or more of the primary studies.
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Short protocol compared with stop short protocol for pituitary suppression in assisted reproduction
Population: women undergoing pituitary suppression in assisted reproduction
Intervention: short protocol
Comparison: stop short protocol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Stop short protocol Short protocol
Live birth and ongoing
pregnancies
per woman randomised
This outcome was not reported by the included trial - -
Clinical pregnancies
per woman randomised
226 per 10001 147 per 1000
(81 to 255)
OR 0.59
(0.3 to 1.17)
230
(1 study)
⊕⊕©©
Low 1,2
No evidence of a differ-
ence between the groups
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
¹The assumed risk in the control group was determined as a mean baseline risk from the study included in the comparison.
²High risk of bias associated with poor reporting of methods in one or more of the primary studies.
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D I S C U S S I O N
Summary of main results
The conclusion from the second update of this systematic review
and meta-analysis is that there was no conclusive evidence that go-
nadotrophin-releasing hormone agonist (GnRHa)-long protocol
was associated with an increase in live birth and ongoing clinical
pregnancy rates in comparison with the GnRHa-short protocol,
although there was moderate evidence of an increase in clinical
pregnancy rates. The finding remained constant after perform-
ing sensitivity analysis, removing studies where the method of
randomisation and the reporting of outcomes were unclear. Sub-
group analysis including four trials studying poor responders only
showed a difference in clinical pregnancy rates, number of oocytes
retrieved, and cancellation rates, favouring the GnRHa-long pro-
tocol when compared with the GnRHa-short protocol.
There was no evidence of a difference in live birth and ongoing
clinical pregnancy rates in comparisons of other protocols of Gn-
RHa for pituitary down-regulation in assisted reproduction treat-
ments.
Apart from two studies where there was evidence of a difference
in the dose of gonadotrophins used when a GnRHa-short proto-
col was compared with a GnRHa-ultrashort protocol, and when a
GnRHa-short protocol was compared with a GnRHa-stop short
protocol, we found no evidence of any difference for any repro-
ductive outcome (either primary or secondary) when GnRHa was
commenced in the follicular phase comparedwith the luteal phase;
stopped, reduced, or continued at the start of stimulation; contin-
ued or not after the oocyte triggering; or lasted for two or three
weeks before stimulation.
Of note, there was very poor reporting of adverse events among
studies in all comparisons, apart from cancellation rates.
Overall completeness and applicability of
evidence
In the comparison of GnRH-long versus GnRH-short protocol
regimens, despite the inclusion of 20 studies, there was no signifi-
cant statistical heterogeneity (I² = 25%), but, as inmany reviews in
assisted reproduction, there was evidence of clinical heterogeneity.
The comparison between a luteal versus follicular start of GnRHa
was based on five trials. None of them mentioned formation of
a cyst, which has been shown to be associated with a follicular
phase start of GnRHa (Jenkins 1996). There is controversy over
whether cysts are associated with poorer outcomes. On the other
hand, there is a risk of inadvertently exposing a pregnancy to
GnRHa if administration is commenced in the luteal phase. Four
per cent of cases of women undergoing in vitro fertilisation (IVF)
have reported such a situation (Ron-El 1990). None of the studies
comparing luteal or follicular phase protocols commented on these
outcomes.
Furthermore, the number of studies comparing various ways of
GnRHa administration in a long protocol was small: three com-
pared the stopping versus the continuation of GnRHa at start of
stimulation, four compared the reduction versus the non-reduc-
tion of the dose during stimulation, one compared the adminis-
tration for two versus three weeks before stimulation, and another
compared the prolongation versus the stopping after the oocyte
retrieval 12 days after the embryo transfer.
Similarly, there were few studies for the rest of the comparisons:
two compared GnRHa-long versus ultrashort, one for short versus
ultrashort, and one for short versus stop short protocols. Hence,
the evidence is insufficient for these comparisons. Also, there were
no data on cost effectiveness and acceptability of these protocols
to women. Importantly, and as in many systematic reviews and
especially Cochrane reviews, we noticed failure of most studies to
report on live birth (four out of 20 in the comparison long versus
short encompassing the maximum of studies) or adverse events.
Moreover, some of the findings only apply to low responders, as
this is an issue of applicability.
Quality of the evidence
Although we included 37 studies in the review, most of themwere
very old. Only 10 were published within the last 10 years; two
were published nine years ago (Fábregues 2005; Simons 2005);
one, seven years ago (Isikoglu 2007); one, five years ago (Zhang
2009); one, four years (Berker 2010); and the remaining five,
within the last two years (Chatillon-Boissier 2012;Ding 2013; Lin
2013; Sarhan 2013; Sunkara 2014). Because of the length of time
elapsed, we were unable to contact most of the authors to get any
missing data, such as the method of randomisation. Intention-to-
treat analysis and an a priori power calculation were not features
of any study except for very few in this review.
The general quality evidence for each comparison was low in al-
most all cases (see the ’Summary of findings’ tables). Common
limitations were failure to report live birth, risk of bias, and im-
precision. Although statistical heterogeneity was not significant in
most analyses, there was clinical heterogeneity, with a wide varia-
tion in the dose regimens and preparation of the GnRHa used.
For the first comparison ’long versus short protocol’, the quality
of the evidence was low for the primary outcome (12 studies), low
for the secondary outcome ’Clinical pregnancy rate’ (20 studies),
and low for cancellation rate (11 studies) (Summary of findings for
the main comparison). We observed a significant variation in the
outcomes ’Number of oocytes retrieved’ and ’Number of ampoules
of gonadotrophins’, most probably due to the way that these data
were presented, such that nopooling of datawas performeddespite
an adequate number of trials (10 and eight studies, respectively).
Ideally, we would like to do a subgroup analysis of prognostic
factors for where there was significant heterogeneity (Analysis
1.3; Analysis 1.4) based on the number of embryos transferred,
previous failed cycles, maternal age, and duration of treatment.
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In the rest of the comparisons, the quality of the studies was low for
those reporting on the primary and secondary outcomes specified
for this review, where reported (in five out of the eight remaining).
Potential biases in the review process
Through the standardised method of identification of studies, we
included all relevant studies. We assessed bias according to the
Cochrane ’Risk of bias’ tool (Higgins 2011) and came to the con-
clusion that most studies were free of selective reporting. Almost
all studies reported pregnancies (clinical). However, most of the
studies (even the most recent) did not report live birth, which
formed part of the primary outcome measure in this review. There
has been considerable debate about what is the best outcome to
report in assisted reproduction technology (ART) studies (Min
2004). Although the most reliable effectiveness of an intervention
in ART is nowadays considered the reporting of live birth rates,
in the current review, the lack of such reporting weakens the ro-
bustness of the results obtained.
Agreements and disagreements with other
studies or reviews
The results for a GnRHa-long versus a GnRHa-short protocol,
with pregnancy rate as the outcome, are similar to those in the
previous published version of this review despite the fact that we
excluded studies analysing gamete intrafallopian transfer (GIFT)
cycles, cross-over trials, and quasi-randomised trials (included in
the last review) in this updated review. This updated review in-
cludes further comparisons that were not part of the initial re-
view. These referred to the GnRH-long protocol: (1) luteal versus
follicular start of GnRHa; (2) stopping and reducing the dose of
GnRHa versus continuing the same dose; (3) administration of
GnRHa for two versus three weeks before stimulation; and (4)
discontinuing versus continuing GnRHa after HCG administra-
tion, and to the GnRH-short protocol (short versus stop short).
There are no non-Cochrane reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When long GnRHa protocols and short GnRHa protocols were
compared, we found no conclusive evidence of a difference in live
birth and ongoing pregnancy rates, but there was moderate qual-
ity evidence of higher clinical pregnancy rates in the long proto-
col group. None of the other analyses showed any evidence of a
difference in birth or pregnancy outcomes between the protocols
compared. There was insufficient evidence to make any conclu-
sions regarding adverse effects.
Implications for research
As adjuvants are almost always used in ART protocols, further
researchwith high quality trials are needed todetermine anoptimal
protocol (when to commence and stop GnRHa and its optimal
dose), further identifying the most cost-effective and acceptable
regimen.
We propose comparisons of these protocols using GnRHa in
women stratified by type of subfertility and age.Most importantly,
for all comparisons included in this review (nine), live birth, ongo-
ing pregnancy rates, or both, should be the primary outcome re-
ported, along with adverse events, as GnRHa protocols have been
associated with high incidence of ovarian hyperstimulation syn-
drome (OHSS) and miscarriage rates. Finally, further parameters
should comprise the outcomes of interest, such as the acceptability
of the regimens, their cost, and the woman’s preference.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acharya 1992
Methods Randomised trial
The method of allocation was not described
The trial was not blinded
Participants Couples with all causes of infertility (unexplained: 20%, male factor: 7%, endometriosis:
18%, tubal factor: 55%)
Interventions Long follicular GnRHa protocol with buserelin acetate 200 µg I/M x 5 daily from day 2
for at least 13 days until ovarian suppression, then 4 ampoules of HMG daily x 3, then
3 ampoules x 1 day, then 2 ampoules daily thereafter and adjusted based on the response
versus short GnRHa protocol with buserelin acetate (dose as above) and HMG (dose as
above) commencing 1 day later
Outcomes • Clinical pregnancy per started cycle
• Multiple pregnancy
• Number of oocytes retrieved (median and range)
• Median number of ampoules of gonadotrophins used
Notes Participants in the short protocol group received norethisterone 5 mg twice daily from
day 21 of the previous cycle for 7 to 14 days to ensure ovarian suppression and to schedule
the cycle start in such a way that the oocyte retrieval was more likely to occur on a
weekday
60% of participants had 3 embryo transfers in both groups
There was 1 cycle per woman
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocated to 1
or the other protocol using a predetermined
schedule
Allocation concealment (selection bias) Unclear risk The paper did not report allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 87 participants were randomised; all par-
ticipants received treatment and were anal-
ysed
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Acharya 1992 (Continued)
Selective reporting (reporting bias) Unclear risk The published report did not include any
of our 2 primary outcomes (live birth/on-
going pregnancy)
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Berker 2010
Methods Randomised trial
The trial used computer-generated block randomisation with sealed envelopes
Participants 82 poor responder participants who underwent ICSI
Inclusion criteria
• At least 1 of: day 3 serum FSH level > 10 mIU/mL, < 6 total antral follicles, prior
cycle cancellation, prior poor response to COH (peak E2 < 500 pg/mL, < 6 oocytes
retrieved, or both)
• Age > 41
Exclusion criteria
• Participants with only 1 ovary, BMI > 30, PCOS, endometriosis stage III to IV,
endocrine or metabolic disease, chromosomal disorders, and participants whose
partners were azoospermic
Interventions Participants were randomised into 2 groups:
1. the participants in the ultrashort GnRH agonist/GnRH antagonist group (n = 41)
were administered leuprolide acetate at 40 microg sc/bid, started on day 2 of menses
and continued for 3 consecutive days, followed by gonadotrophins, which were
initiated on the last day of leuprolide administration with maximal doses continuing
until HCG day. Once the leading follicle had reached a size of 14 mm, co-treatment
was initiated with the GnRH antagonist cetrorelix at 0.25 mg/day, which was
continued up to HCG injection
2. the participants in the microdose group (n = 41) started to use 40 microg sc/bid
leuprolide acetate on day 2 of menses, and 2 days after initiation of GnRHa,
gonadotropin stimulation was initiated and continued until HCG day
The starting dose of recombinant FSH depended on the age, BMI, and ovarian response
to the previous cycle and increased to a maximum of 450 IU/day depending on the
ovarian response. Dosage of rFSH was individualised after day 5 according to ultrasono-
graphic and hormonal follow-up
Luteal support was initiated on the day of oocyte retrieval and continued until the day
of pregnancy testing with vaginal progesterone
Outcomes • Number of mature oocytes
• Clinical pregnancy rate
• Fertilisation rate
• Implantation rate
• Grade A embryo rate
• Cycle cancellation rate
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Berker 2010 (Continued)
Notes Cycle cancellation rates were similar in the groups
There was 1 cycle per woman
The population was selective group (poor responders)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation was computer gener-
ated using sealed envelopes
Allocation concealment (selection bias) Low risk On the day of stimulation initiation, a
nurse who assigned participants to their
groups opened sealed envelopes with treat-
ment allocation instructions
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not mention blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 82 poor responder participants
underwent 78 COH-ICSI cycles. Of these
participants, 41 received the ultrashort
GnRH agonist/GnRH antagonist proto-
col, and 41 received the microdose flare-
up protocol. Cycle cancellation was carried
out for 2 participants in ultrashort GnRH
agonist/GnRH antagonist protocol group
Selective reporting (reporting bias) Low risk Most of the outcomes of interest except live
birth were reported
Other bias Low risk We suspected no other bias
Cedrin-Durnerin 2000
Methods Randomised trial
Participants 230 infertile women undergoing new or repeated IVF cycles
Exclusion criteria
• Women age 43 or older and those who had chronic anovulation
Interventions Daily subcutaneous injection of Dtrp6-GnRH (decapeptyl, 100 µg/day) from day 1 of
IVF cycle followed by ovarian stimulation with exogenous gonadotrophins 150 IU I/m,
with the dose being adjusted according to response
Women were randomised into 2 groups:
1. GnRHa being injected daily from day 1 of IVF cycle to the time of HCG
administration
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Cedrin-Durnerin 2000 (Continued)
2. GnRH agonist administration of agonist being stopped on the 7th day of the IVF
cycle
Outcomes • Number of HMG ampoules
• Number of oocytes
• Pregnancy rate per started cycle
• Miscarriage rate
Notes 2 variants of the short protocol were used
There was 1 cycle per woman
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random number table was used
Allocation concealment (selection bias) Unclear risk The paper did not report allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 230 women were randomised and received therapy. 30 cycles
were cancelled, and analysis was presented for 200 women. The
paper thoroughly presented reasons for cancellation
Selective reporting (reporting bias) Unclear risk The published report did not include any of our 2 primary
outcomes (live birth/ongoing pregnancy)
Other bias High risk An important group of IVF participants (participants with
chronic anovulation) were excluded from participation. Besides,
2 variants of short protocol were used
Chatillon-Boissier 2012
Methods Prospective randomised trial
Participants 44 “poor responder” participants undergoing an IVF cycle
Interventions Participants were randomised into 2 groups:
1. long agonist half-dose group (20 participants)
2. short agonist group (19 participants)
COH with rFSH 300 to 450 UI/d
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Chatillon-Boissier 2012 (Continued)
Outcomes • Number of retrieved oocytes
• Total number of embryos
• Pregnancy rate per cycle
• Pregnancy rate per retrieval
• Live birth rate
Notes There was 1 cycle per woman
There was no pretreatment prior to initiation of GnRHa in both groups
This was a special category of participants (poor responders)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised from a computer-gener-
ated list of pseudo-randompermutation of blocks of vari-
able size
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 44 participants were randomised; 39 participants re-
ceived treatment (reasons specifically mentioned)
Selective reporting (reporting bias) Low risk The paper reported most outcomes of interest
Other bias Low risk We suspected no other bias
Chen 1992
Methods Randomised trial
The method of allocation was not described
Participants Infertile couples with tubal factor (70%), male factor (10%), endometriosis (18%), and
oocyte donation (2%)
Average female age: 33 years
Interventions 1. Long follicular GnRHa protocol with leuprolide acetate 1 mg s.c. daily from day
2 or 3 until ovarian suppression, then FSH 2 ampoules and HMG 2 to 4 ampoules
daily in divided doses adjusted depending on the response
2. Ultrashort GnRHa protocol with leuprolide acetate (as above) from day 3. Luteal
support with HCG: 1500 IU X 3 and progesterone in oil 50 mg I/M daily
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Chen 1992 (Continued)
Outcomes • Clinical pregnancy rate
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The random sequence generation was not
described
Allocation concealment (selection bias) Unclear risk The paper did not describe allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient reporting of attri-
tion/exclusions to permit a judgement of
’low risk’ or ’high risk’
Selective reporting (reporting bias) Unclear risk The paper did not report ongoing preg-
nancy and live birth, but they were not the
planned outcome measures
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Dal Prato 2001
Methods Prospective randomised
Participants 132 women undergoing COH for IVF/ICSI, aged between 25 and 38 years with infer-
tility caused by tubal idiopathic and male factor infertility
Exclusion criteria
• Cases with active endometriosis or only 1 ovary, or with FSH concentration > 15
IU/L on day 3 of menstrual cycles
• Women with previous COH requiring high doses of gonadotrophins in a long
GnRHa protocol or conversely a known history of risk of severe hyperstimulation
Interventions 1. In group 1 (66 women), pituitary desensitisation was performed with single I/M
injection of triptorelin, 3.75 mg starting from day 21 of the cycle preceding treatment
2. In group 2, 66 women received daily s.c injections of 100 µg triptorelin starting
from day 21 of the preceding cycle. At the onset of menses (start time for FSH
stimulation), the dose was reduced to 50 µg s.c daily until the day of HCG
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Dal Prato 2001 (Continued)
administration
Luteal support - natural progesterone in oil
Outcomes • Pregnancy rate per women
• Number of oocytes
• Number of ampoules of gonadotrophins
• Miscarriage rates
Notes Pregnancy was defined as the presence of gestational sac on ultrasound scan performed
4 weeks after embryo transfer
There was 1 woman per cycle
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done using sealed envelopes containing the
name of 1 of the 2 groups
Allocation concealment (selection bias) Low risk Sealed envelopes were used
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded to the treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 132 women were randomised; all women received treatment
as allocated
Selective reporting (reporting bias) Unclear risk The published report did not include our primary outcome
Other bias Low risk We suspected no other bias
De Placido 1991
Methods Randomised trial
Participants Information not provided
Interventions 1. Long luteal GnRHa protocol with subcutaneous buserelin acetate (0.3 mg x 2
daily from the luteal phase)
2. Short GnRHa protocol with the same dose of buserelin acetate using a short
protocol
Outcomes • Clinical pregnancy rate per started cycle
Notes This trial was a randomised comparison of depot versus daily GnRHa formulation; it
was assumed that allocation to the long or short GnRHa protocol was also randomised.
No data were provided on the number of participants undergoing oocyte retrieval and
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De Placido 1991 (Continued)
embryo transfer
Gonadotrophin administration, method of oocyte retrieval, and luteal phase manage-
ment was not described
Most of the information in the bias table is incomplete as this was an abstract. We wrote
to the authors and did not receive any reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation was not described
Allocation concealment (selection bias) Unclear risk The paper did not describe allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not describe blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was insufficient reporting of attrition/exclusions to permit
a judgement of ’low risk’ or ’high risk’
Selective reporting (reporting bias) High risk Only the clinical pregnancy rate per started cycle was reported
Other bias High risk Data regarding the number of participants and other inclusion
criteria were lacking
Ding 2013
Methods Prospective randomised trial
Participants 96 participants with high response to gonadotrophin stimulation compared with refer-
ence concentrations undergoing IVF/ICSI cycle
Inclusion criteria
• Infertility participants with 8 or more subcapsular follicles of 2 to 8 mm in
diameter in 1 plane in either ovary undergoing IVF treatments
Exclusion criteria
• Basal FSH > 10 IU/l
• Age > 35 years
• BMI > 30 kg/m2
• Ovarian surgery radiotherapy or chemotherapy
• Ovarian dysfunction
• Endometriosis
• Hyperprolactinaemia thyroid dysfunction
• Presence of organic pelvic diseases
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Ding 2013 (Continued)
Interventions 96 participants were allocated to 2 independent groups:
1. GnRH agonist withdrawal group (47 participants): triptorelin was initiated
during the luteal phase of the previous cycle (day 21), 0.1 mg/day for 10 days followed
by 0.05 mg/day until the concentration of serum oestradiol <= 40 pg/ml. Once the
serum oestradiol concentration was 40 pg/ml, the stimulation of the ovaries was
initiated using recombinant FSH (doses ranging from 150 to 250 IU/day). When the
diameter of 1 or more follicles was 14 mm, triptorelin (0.05 mg/day) was withdrawn
for 2 (15/47) or 3 (32/47) days
2. control group (49 participants): triptorelin was administered as in group (1), but
administration of triptorelin (0.05 mg/day) was continued to the day of triggering
ovulation
rFSH administration was administered until the triggering of ovulation in both groups
Outcomes • Implantation rate per transferred embryo
• Clinical pregnancy rate per transfer cycle
• Ongoing pregnancy rate per transfer cycle
• Multiple pregnancy rate per pregnancy
• OHSS (moderate/severe)
Notes Clinical pregnancy was determined by observing a gestational sac by means of echo-
graphic screening at 7 weeks of pregnancy
Ongoing pregnancy was defined as a conception cycle with at least 1 foetal sac with a
positive heartbeat reaching beyond 12 weeks of amenorrhoea
There was 1 cycle per participant
ET in 29 out of 47 participants in group (1)
ET in 26 out of 49 participants in group (2)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by computer software
Allocation concealment (selection bias) Low risk The trial used closed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not mention blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk This study enrolled 96 participants
Oocyte retrieval cycles: 47/47 and 49/49. The number
of retrieved oocytes was reported, but only 54 out of 96
reached ET because on day 3 (18 cycles in the GnRH
agonist withdrawal group and 23 cycles in the control
group), all embryos were cryopreserved. The criteria for
this choice was not mentioned
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Ding 2013 (Continued)
Selective reporting (reporting bias) Low risk ET occurred in 29 out of 47 participants in group (1),
and for 26 out of 49 participants in group (2), ET was
not reported. However, the ongoing pregnancy rate was
reported
Other bias Unclear risk There was insufficient information to assess whether an
important risk of bias existed
Dirnfeld 1991
Methods Randomised controlled trial
Participants Infertile couples with a previously cancelled or unsuccessful IVF cycle owing to inade-
quate response
Mean female age: 33.5 (range = 26 to 40)
Interventions 1. Long GnRHa protocol with buserelin acetate 1000 µg intranasal daily for 15 to
30 days until ovarian suppression, then reduced to 600 µg daily and HMG 2 to 3
ampoules daily
2. Short GnRHa protocol with buserelin acetate 600 µg intranasal daily from day 1
and HMG 2 to 3 ampoules from day 3
Luteal support from day of oocyte retrieval with progesterone oil 100 mg I/M daily
Outcomes • Number of oocytes
• Number of ampoules of gonadotrophins
• Clinical pregnancy rate per cycle
• Ongoing pregnancy rate per cycle
Notes We contacted the author. Long GnRH protocol was commenced in either luteal or
follicular phase, although no explanation was given regarding how this decision was
made
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random numbered table was used
Allocation concealment (selection bias) High risk Allocation was not concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 54 participants were randomised and received treatment
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Dirnfeld 1991 (Continued)
Selective reporting (reporting bias) Low risk The paper reportedmost of our prespecified relevant out-
comes
Other bias High risk We contacted the authors. Long GnRH protocol was
commenced in either the luteal or follicular phase
Dirnfeld 1999
Methods Prospective randomised controlled trial
Participants 63 participants with previous poor response to COH, high basal FSH (> 8 mIU/ml), or
both, undergoing 78 IVF-ET cycles
All causes of infertility were included
Exclusion criteria
• Participants > 42 years of age
• Participants with irregular menstrual cycles (> 42 or < 21 days)
Interventions 1. Group 1 received 1000 µg/day of nasal spray or 0.1 mg/day of s.c. D-trp-LHRH
(Decapeptyl). Treatment with GnRHa was started in the mid-luteal phase and ended at
down-regulation
2. In group 2, ovarian down-regulation was performed in an identical manner and
was continued through the follicular phase until the HCG administration
Outcomes • Number of oocytes
• Number of ampoules of gonadotrophins
• Clinical pregnancy rate per cycle
• Ongoing pregnancy rate per cycle
Notes There was more than 1 cycle per participant. Outcomes were described as per cycle
Clinical pregnancywas defined as presence of intrauterine gestational sac onfirst trimester
USG, andongoingpregnancywas defined as 1 that progressed beyond20weeks’ gestation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although the authors mentioned that a ran-
dom number table was used to generate ran-
dom sequence, it was not clear how the table
was created
Allocation concealment (selection bias) Unclear risk The paper did not report allocation conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
55Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dirnfeld 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 63 women agreed to participate in the trial,
but 78 were included in analysis (78 cycles).
It was not clear if 63 or 78 participants were
randomised
Selective reporting (reporting bias) Unclear risk Neither adverse outcomes were mentioned
nor live birth rates
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Fenichel 1988
Methods Randomised trial
Allocation was done by drawing lots
Participants Inclusion criteria
• Women with tubal factor infertility
• No more than 3 previous IVF cycles
• Female aged < 38 years (mean: 31 years)
• Partner with normal semen analysis
Interventions 1. Long luteal GnRHa protocol with depot triptorelin 3.75 mg i.m. then 15 days
later HMG 4 ampoules daily x 4 days, then dose adjusted according to response
2. Short protocol with triptorelin 0.1 mg s.c. daily from cycle day 2 with HMG
starting the same day 2 to 4 ampoules x 2 days, then dose adjusted according to
response, luteal phase support 1500 IU HCG i.m. x 2
Outcomes • Clinical pregnancy rate per started cycle
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins used
Notes The study also included an arm treated with clomiphene citrate and HMG without
GnRHa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation was achieved
through drawing lots
Allocation concealment (selection bias) High risk The paper did not conceal allocation
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
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Fenichel 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 30 women were randomised; all received
treatment
Selective reporting (reporting bias) Unclear risk Our primary outcome was not reported
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Foulot 1988
Methods Randomised trial
Allocation was done by drawing lots
The trial was not blinded
Participants Infertile couples
Mean female age: 32 years
Exclusion criteria
• Women with polycystic ovaries
Interventions 1. Long follicular GnRHa protocol with buserelin 0.3 ml subcutaneously daily for
14 days, then HMG 2 to 4 ampoules daily
2. Short GnRHa protocol with buserelin (same dose) from day 2 and HMG 1
ampoule on days 2 and 3, then 2 ampoules daily from day 4
Luteal phase support with uterogestan from day of oocyte retrieval
Outcomes • Clinical and ongoing pregnancy rate per started cycle/per oocyte retrieval/per
embryo transfer
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins
Notes A measure of variance was not given for the number of oocytes and ampoules of go-
nadotrophins
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done by drawing lots
Allocation concealment (selection bias) Unclear risk The paper did not report allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not report blinding
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Foulot 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100 participants were randomised; all re-
ceived treatment
Selective reporting (reporting bias) Low risk The ongoing pregnancy rate was reported,
but adverse outcomes were not
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Frydman 1988
Methods Randomised controlled trial
Participants 186 infertile couples with predominantly tubal factor (90%)
Exclusion criteria
• Poor responders in previous IVF cycles (defined by cancelled cycles because of low
estradiol)
Interventions 1. In group 1, pituitary desensitisation was obtained by s.c. injection of buserelin
(300 µgm twice daily) from day 2 followed by HMG or FSH 2 ampoules twice daily
for 7 days, then adjusted based on response
2. Short GnRHa protocol: DTRP6-LHRH 0.1 mg s.c. daily from day 1 or 2
followed by HMG or FSH 2 ampoules daily from day 3
Luteal phase support with dydrogesterone 30 mg daily
Outcomes • Clinical and ongoing pregnancy rate
• Miscarriage
• Number of oocytes retrieved
Notes Participants were randomised to receive HMG and FSH in both protocols (2 interven-
tions)
We included the article after internal discussion with SB (as other systematic reviews
have shown that FSH and HMG are equivalent)
Although outcomes measured the number of oocytes retrieved, we did not include in
meta-analysis as there was a statistically significant difference in the oocytes retrieved in
both groups in the HMG and FSH group within the long and short protocol group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of allocation was not described; we wrote to
the trial authors but did not receive any reply
Allocation concealment (selection bias) Unclear risk The paper did not report allocation concealment
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Frydman 1988 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 186 participants were randomised; all received treatment.
Our outcomes were reported
Selective reporting (reporting bias) Low risk Most relevant outcomes were reported (ongoing preg-
nancy rate was reported, but adverse outcomes were not)
Other bias Unclear risk There was insufficient information to assess whether an
important risk of bias existed
Fábregues 2005
Methods Prospective randomised study
Participants 150 consecutive infertile women undergoing their first cycle of IVF/ICSI fulfilling
Inclusion criteria
• Regularly menstruating (26 to 33 days)
• Aged 26 to 40 years with a normal BMI (19.5 to 28.0)
All women had normal ovaries and no previous surgery; none of them had occult ovarian
failure on the basis of their basal FSH < 12 IU/L
Interventions 1. Group 1: pituitary desensitisation was achieved by subcutaneous administration
of triptorelin acetate (decapeptyl 0.1 mg/day) started in the mid-luteal phase of the
previous cycle and continued until administration of HCG
2. Group II: standard daily dose of triptorelin acetate was reduced to 0.05 mg once
the ovarian suppression was confirmed and stimulation with recombinant FSH was
commenced
Outcomes • Clinical pregnancy
• Number of oocytes
Notes Intention-to-treat analysis was not done
There was 1 cycle per woman
A total dose of gonadotropin with variance was given rather than number of ampoules
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated
Allocation concealment (selection bias) Low risk Sealed envelopes were used
59Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fábregues 2005 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 150 women were randomised; all received treatment
(13 cycles were cancelled due to low response - there
were analyses for 137 women). Although there were 75
women in each group, full data was only reported for
68 and 69 women, respectively
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Low risk Although the paper gave an a priori sample size cal-
culation, there was insufficient information to assess
whether an important risk of bias existed
Garcia-Velasco 2000
Methods Prospective randomised controlled trial
Participants 70 women who were undergoing stimulation for IVF/ICSI cycles and were previous low
responders
Inclusion criteria
• Women had to have at least 1 previous cycle cancelled due to poor response and
FSH < 12 IU/ml
Exclusion criteria
• There was no exclusion criteria or age limit
Interventions 1. GnRHa was started in the luteal phase of the previous cycle (leuprolide acetate 1
mg/day s.c.) on day 21 and was continued in group 1 up until the day of HCG
2. In group 2, GnRHa was stopped as soon as gonadotrophins were commenced.
On day 1 and 2 of stimulation, 3 ampoules of HMG were administered together with
5 ampoules of FSH. On days 3, 4, and 5 of ovarian stimulation, 2 ampoules of HMG
and 3 ampoules of FSH were administered
Outcomes • Pregnancy per cycle/per woman
• Pregnancy per transfer
• Number of cancellations due to poor response
• Number of oocytes obtained
Notes There was 1 cycle per woman
This was a special category of participants (poor responders)
Risk of bias
Bias Authors’ judgement Support for judgement
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Garcia-Velasco 2000 (Continued)
Random sequence generation (selection
bias)
Low risk A computerised random number list was used
Allocation concealment (selection bias) Unclear risk The paper did not describe the method of
allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not report blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 70 women were randomised; all women were
included in analysis
Selective reporting (reporting bias) Unclear risk There was no mention of our primary out-
comes
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Hazout 1993
Methods Randomised trial
Allocation was done by using permutation blocks of 8
Participants Inclusion criteria
• New or repeat IVF participants with either unexplained infertility (31%) or tubal
factor (69%)
• Females aged less than 38 years and duration of infertility < 4 years
Interventions 1. Long follicular GnRHa protocol with decapeptyl, 3.75 mg depot, administered
cycle day 2 then 18 days later or when estradiol suppression was achieved, HMG at 4
ampoules daily (or dose based on participant’s response in previous cycles) for 5 days
with dose adjusted thereafter depending on the response
2. Short protocol with decapeptyl 0.1 mg daily for 7 days starting cycle day 2, then
starting cycle day 4, HMG 3 ampoules daily for 5 days, with dose adjusted thereafter
depending on the response. Luteal phase support with HCG 1500 IU on day of
transfer and 4 days later (if estradiol < 2500 pg/ml) or with progesterone suppositories
300 mg daily (if estradiol > 2500 pg/ml)
Outcomes • Clinical pregnancy rate per cycle started, per oocyte retrieval, per embryo transfer
• Number of oocytes mature retrieved
• Number of ampoules of gonadotrophins used/cycle
Notes The number of pregnancies in the short protocol groupwas estimated from the pregnancy
rates given
Risk of bias
61Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hazout 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation was done by using a permuta-
tion block of 8
Allocation concealment (selection bias) High risk Allocation was not concealed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not report blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 182 women were randomised. 96 received
the long protocol. 84 reported in the text
versus 86 in the table received the 7-day
protocol. There were no cancellationsmen-
tioned for the 7-day group
Selective reporting (reporting bias) Unclear risk There was no mention of our primary out-
comes
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Hedon 1988
Methods Randomised trial
Participants Infertile couples (tubal factor: 53%, unexplained: 19%, endometriosis: 7%, combined
cause: 22%), excluding those with male factor infertility and ovulation disorders
Interventions 1. Long follicular GnRHa protocol with buserelin 0.3 ml s.c. x 2 daily days 2 to 14,
then HMG 4 ampoules x 3 days, 2 ampoules x 2 days, then dose adjusted based on
response
2. Short GnRHa protocol with buserelin (as above) from day 2 together with HMG
1 ampoule x 2, 1.67 ampoules x 3 days, then dose adjusted based on response
Luteal support HCG 1500 IU x 2
Outcomes • Clinical and ongoing pregnancy rate per started cycle/per oocyte retrieval/per
embryo transfer
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins used
Notes A measure of variance was not given for the number of oocytes retrieved and number of
gonadotropin ampoules
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not described
Allocation concealment (selection bias) Unclear risk The paper did not report allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Although 120 women were randomised, data were available for
only 112 women; we wrote to the authors but did not receive
any reply. 120 participants were randomised, but 56 participants
received treatment in each group = 8 participants were not in-
cluded due to the reasons mentioned
Selective reporting (reporting bias) Low risk Most relevant outcomes, including 1 of the primary outcomes
in this review, were reported except adverse outcomes
Other bias Unclear risk There was insufficient information to assess whether an impor-
tant risk of bias existed
Isikoglu 2007
Methods Prospective randomised trial
Participants 181 women undergoing IVF/ICSI
Interventions GnRHa was administered from the 21st day of the preceding cycle. Participants were
divided into 2 groups:
1. (n = 90 participants): participants were continuously administered GnRHa for 12
days after embryo transfer
2. (n = 91 participants): GnRHa was stopped on the day of human chorionic
gonadotropin administration
Outcomes • Number of gonadotropin ampoules used
• Number of mature oocytes recovered
• Rates of testicular sperm usage
• Number of embryos transferred
• Cycle and transfer cancellation rates
• Clinical pregnancy rate
• Implantation rate
• Live birth rate
Notes Participants were randomised by a computer-generated list
Risk of bias
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Isikoglu 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved by a computer-generated
list
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk Only embryologists were reported to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 181 participants were randomised; all participants were
included and mentioned in the analysis
Selective reporting (reporting bias) Low risk All our outcomes were mentioned
Other bias Low risk We suspected no other bias
Kingsland 1992
Methods Randomised trial
Allocation was concealed using sealed envelopes
Participants Couples with all causes of infertility (tubal factor: 50%, unexplained: 29%, male factor:
14%, endometriosis: 5%) undergoing their first IVF attempt
Interventions 1. 2 ampoules per day of HMG were administered by i.m. injection (starting from
day 2 of the cycle, 3 ampoules were administered if the woman was over 35 years of age)
2. In addition to regimen in group A, participants were given clomiphene citrate
100 mg/day from day 2 to 6 of the menstrual cycle
3. Ultrashort GnRHa protocol with buserelin 500 µg s.c on days 2, 3, and 4 and
HMG from day 3 versus
4. Long follicular GnRHa protocol with buserelin 200 µg s.c. daily from day 1 until
pituitary desensitisation, then HMG 3, 4, or 5 ampoules daily (for participants ≤ 35
years, > 35 years, and > 40 years, respectively), versus luteal phase support with HCG
2000 IU i.m. x 2
Outcomes • Clinical pregnancy and live birth rate per cycle/per embryo transfer
• Number of oocytes
• Number of ampoules of gonadotrophins
Notes Women were randomised into 4 groups: A + B without GnRHa and C +Dwith GnRHa
Risk of bias
Bias Authors’ judgement Support for judgement
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Kingsland 1992 (Continued)
Random sequence generation (selection
bias)
Low risk A random number table was used
Allocation concealment (selection bias) Low risk Sealed envelopes were used
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 308 women were randomised into 4
groups; all participants received treatment.
The number of cancelled cycles was re-
ported
Selective reporting (reporting bias) Low risk Most of our outcomes were reported
Other bias Low risk We suspected no other bias
Kondaveeti-Gordon 1996
Methods Randomised prospective study
Participants Women undergoing IVF/ICSI (first cycle only)
Interventions 1. Down-regulation (buserelin acetate intranasal spray 6 times daily - total daily dose
of 1200 µg) commenced on day 1 or day 21 of the cycle
Outcomes • Pregnancy rate
• Number of oocytes obtained
Notes There was 1 cycle per woman. Although an a priori power calculation was done, the
study was powered only to detect difference in the use of gonadotrophins
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated with a per-
muted block
Allocation concealment (selection bias) High risk Allocation was not concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
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Kondaveeti-Gordon 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 86 participants were randomised; all participants re-
ceived treatment and analysed
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was insufficient information to assess whether
an important risk of bias existed
Lin 2013
Methods Prospective randomised controlled study
Participants 100 participants undergoing IVF/ICSI cycle
Inclusion criteria
• Subfertile participants undergoing first IVF/(ICSI) with tubal factor, male factor,
or unexplained factor
• Undertaking a luteal long protocol
• Basal FSH levels 10 IU/L
• Aged 35 years
Exclusion criteria
• Endometriosis
• Adenomyosi
• Polycystic ovarian syndrome
Interventions In both groups, a single dose of long-acting GnRHa (Diphereline®, 1.25 mg, 3.75 mg/
ampoule) was administered on days 20 to 22 of the mid-luteal phase. Participants were
divided into 2 groups:
1. group A: initiation of gonadotrophins occurred on the 21st day
2. group B: initiation of gonadotrophins on the 14th day after GnRHa
administration
Ovarian stimulation was performed with an initial gonadotropin dose of 75 to 300 IU
(recombinant FSH (rFSH) or human menopausal gonadotropin (HMG))
Outcomes 1. Clinical pregnancy rate
2. Implantation rate
3. Live birth rate
4. Miscarriage rate
5. Moderate OHSS rate
Notes Clinical pregnancy was defined as a positive serum HCG result, with US evidence of a
gestational sac and foetal heartbeat
Miscarriage rate was defined as the proportion of participants with an initially positive
pregnancy test and US evidence of a gestational sac with a foetal pole where pregnancy
failed to develop by 12 weeks of gestation
Live birth rate was defined as pregnancies over 28 weeks per treatment cycle of ET
Luteal phase support was started immediately after oocyte retrieval
Risk of bias
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Lin 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved by computer-
generated random numbers 2 weeks after
GnRHa administration
Allocation concealment (selection bias) Unclear risk The paper did not report allocation conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100 participants from random visits who
met the inclusion criteria were recruited. 85
participants were included in analysis. How-
ever, all reasons and numbers mentioned
for the 15 participants were missing (6 cy-
cles were cancelled due to low response or
privacy reasons; ET was cancelled in 6 cy-
cles due to no useable embryos or high risk
OHSS - there was no extra justification)
Selective reporting (reporting bias) Low risk Relevant outcomes were reported
Other bias Low risk We suspected no other bias
Loumaye 1989
Methods Randomised trial
The method of allocation was not described
Participants Inclusion criteria
• Couples with tubal factor infertility
• Females aged < 40 years
Interventions 1. Long luteal GnRHa protocol with buserelin 300 µg intranasally, 3 times daily,
then HMG 3 ampoules daily from day 3 of subsequent menses
2. Short GnRHa protocol with buserelin (as above) from day 1 followed by 3
ampoules of HMG daily from day 3
Luteal phase support with HCG 1500 IU intramuscular on days 6 and 9 after retrieval
Outcomes • Clinical pregnancy rate
• Ongoing pregnancy rate
• Number of oocytes obtained
Notes -
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Loumaye 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not de-
scribed
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18 participants were randomised; all re-
ceived therapy. Cancellation was not men-
tioned; 17 out of 18 transferred
Selective reporting (reporting bias) Low risk Our prespecified relevant outcomes were
reported, including ongoing pregnancy
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Pellicer 1989
Methods Randomised trial
The method of randomisation was not known
Participants Women undergoing IVF between 15 January and 31 May 1998
Inclusion criteria
• Women who had both ovaries and normal ovarian function prior to IVF
Interventions Pituitary desensitisation was achieved with 300 µgm of buserelin twice a day
1. Group 1 and 2 commenced GnRHa in luteal phase (group 1: 4 to 7 days after
ovulation, whereas group 2 commenced 8 to 10 days after ovulation)
2. Group 3 commenced GnRHa in the follicular phase
HMG + FSH were used for stimulation. Standard dose was used up to day 5, which was
then modified according to individual response
Outcomes • Number of oocytes
• Clinical pregnancy
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Pellicer 1989 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocation into
groups, but it was not clear how this was
done
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The total number of participants ran-
domised was not mentioned in the meth-
ods. In the results section, 44 participants
were mentioned as receiving treatment af-
ter randomisation
Selective reporting (reporting bias) Unclear risk There was no mention of our primary out-
comes
Other bias High risk Group 1 and 2 commencedGnRHaon dif-
ferent days, although bothwere in the luteal
phase
Ron-El 1990
Methods Random allocation into 2 groups
Participants 216 consecutive women undergoing IVF/ICSI
Interventions 1. GnRHa (3.2 mg decapeptyl single intramuscular injection) was given either on
day 1 to 3 of the menstrual cycle (group A) or on day 22 (Group B)
HMG was used for stimulation with a standard dose for the first 4 days followed by
individual adjustment of doses
Outcomes • Number of oocytes retrieved
• Ampoules of gonadotrophins required
• Clinical pregnancy
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although the paper reported random allocation, it
did not describe the exact method
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Ron-El 1990 (Continued)
Allocation concealment (selection bias) Unclear risk The paper did not describe allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 216 women were randomised; all were mentioned
to have received treatment
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk Therewas insufficient information to assesswhether
an important risk of bias existed
San Roman 1992
Methods Randomised trial
Participants 55 women undergoing IVF-ET regardless of previous cycle response or number of pre-
vious cycles undertaken
Interventions 1. Group 1 received GnRHa (lupron) 1 mg/day s.c. for 10 days commencing on
cycle day 21. After 10 days, if serum estradiol was ≤ 184 pmol/L the GnRHa dose was
reduced to 0.5 mg/day s.c. and HMG was administered 225 IU I/M. GnRHa was
continued until HCG (long protocol)
2. Group 2 commenced concurrent therapy with GnRHa 0.5 mg/day s.c. and HMG
225 IU I/M beginning on menstrual cycle day 3. Concurrent treatment with GnRHa +
HMG was continued for 5 days. GnRHa was continued until HCG (short protocol)
Outcomes • Cycle cancellation
• Number of ampoules of gonadotrophins
• Clinical pregnancy
• Live birth
Notes A clinical pregnancy was defined as USG visualisation of gestational sac or pathological
evidence of trophoblast
GnRHa dose was reduced at the start of stimulation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not described
Allocation concealment (selection bias) High risk Allocation was not concealed
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San Roman 1992 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 55 women were recruited and randomised. All women received
treatment; outcomes were not reported for 5 of them (low re-
sponse)
Selective reporting (reporting bias) Low risk Our prespecified relevant outcomes were reported
Other bias Unclear risk There was insufficient information to assess whether an impor-
tant risk of bias existed
Sarhan 2013
Methods Prospective randomised controlled study
Participants 181 infertile participants undergoing ICSI cycles
Interventions All participants started treatment with subcutaneous daily injections of GnRHa (trip-
torelin). Participants were divided into 2 groups:
1. group A (66 participants): treatment with the agonist was started on the first or
second day of the menstrual period
2. group B (115 participants): treatment with the agonist was started on day 20 to
22 of the cycle
In both groups, the agonist treatmentwas continueduntil the day ofHCGadministration
Outcomes • Days of stimulation
• Number of ampoules of gonadotrophins used
• Number of oocytes retrieved per cycle
• Number of embryos per cycle
• Fertilisation rate
• Cleavage rate
• Pregnancy rate
• Clinical pregnancy rate per cycle and per ET
Notes Clinical pregnancy was defined by the presence of intrauterine gestational sac(s) with
pulsating heart beats on trans-vaginal ultrasound scan at 5 to 6 weeks’ gestation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was achieved using closed
envelopes
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Sarhan 2013 (Continued)
Allocation concealment (selection bias) Unclear risk The paper did not report allocation conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not report blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 181 participants were randomised. All par-
ticipants were mentioned as included in
analysis
Selective reporting (reporting bias) Unclear risk There was no mention of our primary out-
comes
Other bias Unclear risk There was insufficient information to assess
whether an important risk of bias existed
Simon 1994
Methods Prospective randomised trial
Participants 42 women undergoing a fresh cycle of IVF due to tubal obstruction
Inclusion criteria
• Women less than 39 years old who had 2 ovaries and normal ovarian function
Exclusion criteria
• Suspected male factor
Interventions After pituitary down-regulation (serum estradiol < 30 pg/ml, serum progesterone < 0.
5 ng/ml, and the absence of any ovarian follicle > 10 mm in size), participants were
allocated into 2 groups:
1. group A continued to receive the standard dose of 0.5 mg/day LHRHa
2. group B were given a reduced dose of 0.1 mg/day of LHRHa
Luteal support was provided with intramuscular progesterone injection in oil
Outcomes • Number of oocytes retrieved per woman
• Clinical pregnancies/woman
• Implantation rate
• Pregnancy per ET
Notes There was 1 cycle per woman
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation was not described
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Allocation concealment (selection bias) Unclear risk The paper did not report allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk In the text, it was reported that 43 women were ran-
domised and received treatment, while in the abstract
and tables, it is reported that 42 women received treat-
ment
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was an insufficient rationale or evidence that an
identified problem would introduce bias
Simons 2005
Methods Double-blind, randomised, multicentre study
Participants 178 women undergoing IVF/ICSI treatment, history of spontaneous regular cycle be-
tween 24 and 35 days
Inclusion criteria
• Aged 18 to 38 years at the time of screening
• BMI < 33
Exclusion criteria
• Women with either a history of PCO or incipient ovarian failure
• Ovulation induction treatment or an IVF/ICSI attempt in the 2 months before
the study
• Poor response to stimulation in previous cycle
Interventions 1. Group L received the traditional long protocol, i.e., mid-luteally started
triptorelin was continued until the day of HCG injection
2. In group M, triptorelin continued up to and including the fourth day of HMG
treatment
3. In group S, triptorelin was stopped at the first day of HMG treatment
Outcomes 1. Occurrence of premature LH surge
2. Number of oocytes, implantation rate, clinical and ongoing pregnancy, dose of
triptorelin
Notes Comparison groups for this review: group L versus group S
Risk of bias
Bias Authors’ judgement Support for judgement
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Simons 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated
Allocation concealment (selection bias) Low risk Allocation was concealed in a sealed enve-
lope in a central locker
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and personnel blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 178 participants were randomised; 18 par-
ticipants were not included in the anal-
ysis. (Reasons and numbers were men-
tioned thoroughly: discontinuation during
the stimulation phase or missing LH data)
Selective reporting (reporting bias) Low risk All our prespecified relevant outcomeswere
reported
Other bias Low risk There was insufficient rationale or evidence
that an identified problemwould introduce
bias
Sunkara 2014
Methods Prospective randomised controlled trial
Participants 111 women with previous poor ovarian response undergoing IVF
Exclusion criteria
• Women aged > 40 years and women with a single ovary
Interventions Women were allocated to 3 groups:
1. long GnRH agonist group: pituitary down-regulation with nafarelin nasal spray
400 mg twice daily was commenced in the midluteal phase of the menstrual cycle and
continued for 2 weeks. Ovarian stimulation was commenced with gonadotropin
injections at a dose of 450 IU/day and continued with a reduced dose of nafarelin 200
mg twice daily until the administration of HCG injection
2. short GnRH agonist group: nafarelin nasal spray was commenced on day 2 or 3
of the cycle. Nafarelin was administered at a dose of 200 mg twice daily followed by
gonadotropin injections at a dose of 450 IU/day commenced 1 day later. Both nafarelin
and gonadotropin injections were continued until the administration of HCG
3. GnRH antagonist group
Outcomes 1. Number of oocytes retrieved
2. Mature oocytes retrieved
3. Clinical pregnancy rates
4. Ongoing pregnancy rates
5. Gonadotropin consumption
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Sunkara 2014 (Continued)
6. Duration of stimulation
7. Cycle cancellation rate
8. Fertilisation rate
9. Cycles reaching ET
Notes Participants were allocated to 1 of the 3 study groups by a third party, distant, internet-
based block randomisation to ensure complete allocation concealment. The clinician
performing the OR and the embryologist involved were blinded to the treatment allo-
cation
The participants were poor responders
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computerised
Allocation concealment (selection bias) Low risk Sealed envelopes were used
Blinding (performance bias and detection
bias)
All outcomes
Low risk The clinician performing theOR and the em-
bryologist involved were blinded to the treat-
ment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 111 women were randomised. 19 women did
not receive the allocated intervention (rea-
sons mentioned: 3 conceived spontaneously;
16 decided to postpone IVF treatment)
Selective reporting (reporting bias) Low risk All our planned outcomes were reported
Other bias Low risk The study appeared to be free of other sources
of bias
Tan 1992
Methods Randomised trial
Participants Couples with all causes of infertility (unexplained: 25%, male factor: 11%, endometrio-
sis: 5%, tubal factor: 58%) undergoing their first cycle of IVF
Interventions 1. Long follicular GnRHa protocol with buserelin acetate 200 µg subcutaneous
daily from day 1 for at least 14 days until ovarian suppression, then HMG 3, 4 or 5
ampoules daily based on age
2. Short protocol GnRHa protocol with buserelin (as above) from day 2 and HMG
from day 3
Luteal support with HCG 2000 IU x 2
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Tan 1992 (Continued)
Outcomes • Clinical pregnancy rate
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins
Notes Significantly more cleaved embryos were available for transfer in participants on the long
versus the short protocol
A measure of variance was not given for the number of oocytes retrieved and number of
ampoules of gonadotrophins
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random tables were used
Allocation concealment (selection bias) Low risk Sealed envelopes were used
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 91 women were randomised and received treatment
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was insufficient information to assess whether an impor-
tant risk of bias existed
Tasdemir 1995
Methods Randomised trial
Participants Couples with all causes of infertility (tubal factor: 40%, male factor: 29%, unexplained:
19%, endometriosis: 10%) undergoing their first IVF cycle
Interventions 1. Long luteal protocol with buserelin acetate 900 µg intranasal daily then cycle day
2
2. Short GnRHa protocol with buserelin (as above) from cycle day 1 and HMG as
above
Luteal phase support with 2000 IU HCG x 3
Outcomes 1. Clinical pregnancy rate
2. Live birth rate
Notes The trial author confirmed that the study was randomised
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The exact method of randomisation was not known
Allocation concealment (selection bias) Unclear risk The paper did not describe allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 90 participants were randomised. The number of participants
allocated to each group was not mentioned in the text or ta-
bles either. The number of participants receiving treatment and
analysed was not mentioned
Selective reporting (reporting bias) Low risk Live birth rate was reported
Other bias High risk The median number of embryos transferred was 4 with the long
GnRHa protocol and 1 with the short protocol. We obtained
confirmation of randomisation in the original review. We did
not receive any reply to further queries. There was no power
calculation and no mention of the exact number of participants
in each group
Urbancsek 1996
Methods Prospective randomised trial
Participants 124 women undergoing IVF due to tubal factor or unexplained infertility
Interventions 1. Buserelin acetate (intranasally 300 µg 4 times a day) starting on day 1 of cycle or
in the mid-luteal phase for pituitary down-regulation
Outcomes 1. Live birth
2. Clinical pregnancy
3. Ongoing pregnancy
Notes There was more than 1 cycle per participant
A measure of variance for the number of oocytes was not given
Only unexplained infertility and tubal factor were included
Therewasmore than1 cycle perwoman; data for only 1 cyclewere not available separately
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was centrally prepared
Allocation concealment (selection bias) Unclear risk The paper did not report allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis was not done
Selective reporting (reporting bias) Low risk Live birth and other prespecified outcomeswere reported
Other bias Unclear risk There was insufficient information to assess whether an
important risk of bias existed
van de-Helder 1990
Methods Randomised trial
Participants Inclusion criteria
• Infertile women with blocked tubes and regular cycles
• Female aged < 41 years (mean age: 32; range = 23 to 40 years)
• Partners with normal semen analysis
Interventions 1. Long luteal GnRHa protocol with buserelin 200 µg intranasally daily (3 times)
from the mid-luteal phase until ovarian suppression was confirmed (after which
stimulation with HMG was started)
2. Short GnRHa protocol with buserelin from day 1 at the same dose (with start of
stimulation with HMG from day 4)
Buserelin was continued until the day of HCG administration
Outcomes • Clinical and ongoing pregnancy rates, per started cycle, per oocyte recovery, per
embryo transfer
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins used
Notes The trial included a third group that was randomised not to receive GnRHa. Clinical
pregnancy was defined as foetal heart activity seen on ultrasound
A measure of variance was not provided for the average number of gonadotrophins
ampoules and average number of oocytes retrieved
Risk of bias
78Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van de-Helder 1990 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not described
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 152 participants were randomised; 152 participants received
treatment - there were 23 cancellations, all due to low response
Selective reporting (reporting bias) Low risk Our prespecified outcomes, including ongoing pregnancy rate,
were reported
Other bias Unclear risk There was insufficient information to assess whether an impor-
tant risk of bias existed
Weissman 2003
Methods Randomised prospective study
Participants 60 low responders (from previous cycle) who were undergoing IVF
Poor responders were defined as fewer than 5 oocytes retrieved, 3 or fewer follicles 16
mm or larger on the day of cancellation or serum E2 less than 500 pg/ml on the day of
HCG administration
Only participants with FSH less than 20 IU/L were included
Interventions 1. Short protocol (high dose GnRHa (500 µg/day) was administered for first 4 days
followed by a standard agonist dose (100 µg/day)
2. Long protocol (standard GnRHa dose (100 µg/day) used until pituitary down-
regulation after which the agonist dose was halved during stimulation)
Outcomes • Number of oocytes retrieved
• Number of cancellation
• Implantation rate
• Clinical pregnancy
Notes Both short and long protocols were modified protocols
1 cycle per woman
Risk of bias
Bias Authors’ judgement Support for judgement
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Weissman 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 60 participants were randomised; treatment was allo-
cated to all of them
Selective reporting (reporting bias) Low risk Most outcomes of interest were reported
Other bias Unclear risk There was insufficient information to assess whether
an important risk of bias existed
Yang 1996
Methods Randomised trial
Participants Couples with all causes of infertility except severe male factor and polycystic ovarian
syndrome (tubal factor: 52%, unexplained: 28%, endometriosis: 17%, male factor: 3%)
Interventions 1. Long GnRHa protocol with leuprolide acetate 1 mg subcutaneously daily until
ovarian suppression, then dose reduced to 0.5 mg daily together with HMG 3 to 6
ampoules intramuscular daily x 5 days then HMG dose reduced according to the
response
2. A modified short protocol with decapeptyl 0.1 mg s.c. daily from cycle day 1 to 7
with HMG (as above) starting cycle day 3
Luteal support with progesterone vaginal suppositories 200 mg x 2 daily with HCG
1500 IU intramuscular x 4
Outcomes • Clinical pregnancy rate per cycle started
• Number of oocytes retrieved
• Number of ampoules of gonadotrophins required
Notes Long GnRHa was commenced in either the luteal or follicular phase
There was 1 cycle per woman
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not described; we wrote to
the trial authors but received no reply
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Yang 1996 (Continued)
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not report blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 60 participants were randomised; all received treatment, and no
cancellations were reported
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was insufficient information to assess whether an impor-
tant risk of bias existed
Ye 2001
Methods Prospective randomised trial
Participants 109 infertile couples undergoing IVF
Interventions 1. GnRHa long protocol (GnRHa taken by nasal spray 0.9 mg/day starting on day
21 of previous menstrual cycle; gonadotrophins were started once pituitary suppression
was achieved)
2. Short protocol (GnRH agonist 0.45 mg per day commenced on day 2 of the
menstrual cycle, and gonadotrophins were commenced on the same day)
Outcomes • Ampoules of gonadotrophins required
• Number of oocytes retrieved
• Pregnancy rate
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation was used
Allocation concealment (selection bias) High risk Allocation was not concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 109 participants were randomised; all received therapy
as shown in the tables
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Ye 2001 (Continued)
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was insufficient information to assess whether an
important risk of bias existed
Zhang 2009
Methods Prospective randomised trial
Participants 88 participants with infertility due to tubal factor
Inclusion criteria
• Aged < 35 years of age, BMI: 18 ~ 29 kg/m2, duration of menstrual cycle (25 ~
35 days), spontaneous ovulation
• Existence of both ovaries and uterus
• Adequate male sperm quality feasible for IVF fertilisation
Exclusion criteria
• Polycystic ovary syndrome, endometriosis, or severe male factor
• Systemic, endocrine, or metabolic disease
• Undergoing radiotherapy and chemotherapy
• Smokers
• Those taking narcotics
Interventions Participants were divided into 2 groups:
1. short GnRHa group (44 participants)
2. long GnRHa group (44 participants)
Outcomes • Total dose of gonadotrophins
• Number of oocytes retrieved, cleavage and fertilisation rates
• Clinical pregnancy and miscarriage rates
• Concentrations of IGF-II and IGFBP-4 in the follicular fluid
Notes The article was in Chinese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation was not mentioned
Allocation concealment (selection bias) Unclear risk The paper did not mention allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The paper did not mention blinding
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Zhang 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88 participants were randomised; all participants re-
ceived treatment. Analyses were mentioned for 88 par-
ticipants (data derived from tables)
Selective reporting (reporting bias) Unclear risk There was no mention of our primary outcomes
Other bias Unclear risk There was insufficient information to assess whether an
important risk of bias existed
BMI: body mass index.
COH: controlled ovarian hyperstimulation.
E2: estradiol.
ET: embryo transfer.
FSH: follicle-stimulating hormone.
GnRH: gonadotrophin-releasing hormone.
GnRHa: gonadotrophin-releasing hormone agonists.
HCG: human chorionic gonadotrophin.
HMG: human menopausal gonadotrophin.
I/M: intramuscular.
ICSI: intracytoplasmic sperm injection.
IGFBP-4: insulin-like growth factor binding protein-4.
IGF-II: insulin-like growth factor II.
IVF: in vitro fertilisation.
IVF-ET: in vitro fertilisation pre-embryo transfer.
LH: luteinising hormone.
OHSS: ovarian hyperstimulation syndrome.
OR: oocyte retrieval
PCOS: polycystic ovary syndrome.
rFSH: recombinant follicle-stimulating hormone.
s.c.: subcutaneously.
US/USG: ultrasonography.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abd Rabo 2012 This paper evaluated the effect of using letrozole in improvement of the results of ICSI/ET in women with
endometriosis using a long agonist protocol
Aflatoonian 2012 This paper assessed the efficacy of low dose HCG in the late follicular phase in controlled ovarian stimulation
using a GnRH agonist protocol
Albuquerque 2013 This was a Cochrane review from the Cochrane Database of Systematic Reviews
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(Continued)
Antoine 1990 This paper compared GnRHa with no GnRHa
Azem 2010 There were no data for comparison after repeated attempts to reach the authors. Only the abstract was
available
Beckers 2000 Participants were randomised into 3 groups. 2 interventions were compared stopping GnRHa on day 3 of
stimulation as well as luteal support
Bloch 2011 This paper used the same study population as in Azem 2010, assessing phycological outcomes
Braendle 1989 Allocation to a short or long protocol was sequential and not random
Buvat 1993 Quasi-randomisation was used (randomised by year of birth)
Cambiaghi 2011 This paper compared 2 different regimens of long protocols
Check 1992 This was a randomised trial (allocation was based on the last digit of the participant’s social security number)
comparing long versus ultrashort protocol, but we excluded as it had a cross-over design
Cheon 2008 This paper compared 2 regiments for the same GnRHa protocol
Corson 1992 This study compared 3 protocols ((a) stopping GnRHa at start of stimulation, (b) reducing GnHa at start
of stimulation, (c) no GnRHa at all for both IVF as well as GIFT cycles). We could not extract data on IVF
cycles separately. We contacted the authors, but separate data were not available, as the study was very old
Dessolle 2011 This was a prospective non-randomised study
Devroey 1994 This was a non-randomised pilot study
Dor 1992 This study compared GnRHa with no GnRHa
Eftekhar 2013 This trial compared daily injection with a single intramuscular dose of GnRHa
Elgendy 1998 This paper reported quasi-randomisation (alternate IVF numbers)
Faber 1998 This was a non-randomised study
Ferraretti 1996 This was a retrospective data analysis
Fujii 1997 This paper reported quasi-randomisation (group allocated based on day of visit to the unit)
Garcia 1990 The method of allocation to short or long luteal GnRHa protocol was stated to be prospective, but no
information was provided on whether randomisation was used. We attempted to contact the authors, but
received no reply
Gersak 1994 The paper compared GnRHa with no GnRHa
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Gianaroli 1994 This study compared 3 different long protocols: (a) buserelin 0.5 mg s.c. twice a day 15 days prior to ovarian
stimulation, (b) a single dose of long-acting triptorelin (3.75mg) 15 days before ovarian stimulation, (c) long-
acting triptorelin 4 weeks prior to ovarian stimulation followed by daily administration of 0.1 mg agonist
until HCG injection. This did not follow any of the defined comparisons in the protocol
Gizzo 2014 Randomisation was according to the luteal phase supplementation
Harrison 1994 This paper compared GnRHa with no GnRHa
Huang 2012 This was a retrospective study
Jinno 1996 This paper was an evaluation of bromocryptine in 1 of 2 groups
Jinno 2009 This paper compared different doses of the same GnRH agonist
Ku 2005 This was a retrospective study
Kubik 1990 The paper compared GnRHa with no GnRHa
Kuc 2011 This was a retrospective study
Li 2012 This paper compared 2 different doses of Lupron Depot in GnRH analogues in a long 21 protocol
Liu 2012 This was a non-RCT
Lorusso 2004 This was a non-randomised study
Loutradis 1998 This paper compared 2 regiments in long protocols
Marcus 1993 This was a randomised trial (allocation was by the last digit of the medical file number) comparing long
versus ultrashort protocol. We excluded it because of its cross-over design
Maroulis 1991 192 women who were referred for IVF. Randomly allocated to group A (protocol with pure FSH-HMG),
group B (received GnRHa in the luteal phase), or group C (received GnRHa in the follicular phase). During
the first 9 months, participants were randomly allocated between protocol A and B (in 2:1 ratio) whereas for
the last 11 months between protocols A, B, and C
McKenna 1989 Allocation was not random
Mochtar 2011 Allocation depended on the size of leading follicles
NCT00436319 This was a stopped trial (personal communication with authors)
NCT02342197 The primary outcome was the number of oocytes retrieved (not the prespecified outcomes of our review)
Neuspiller 1998 This was a study on oocyte donors
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Norman 1991 Allocation to a short or long luteal GnRHa protocol was not random, but based on clinical grounds
Padilla 1991 Participants were allocated to 5 different protocols based on the results of the Lupron screening test. Those
with pattern C were randomised into 1 of 3 protocols in phase 1: (1) no GnRHa, (2) double dose GnRHa
with flare protocol (not clear whether this was short or ultrashort protocol), or (3) luteal phase GnRHa. In
phase 2, they were all given luteal phase GnRHa
Pantos 1994 This study was quasi-random (alternate)
Remorgida 1989 We excluded as only GIFT cycles were included
Rodrigues 2014 This was a non-RCT
Ron-El 1992 Allocation to ultrashort GnRHa protocol was based on the ability of the participant to attend the clinic on
day 1 or 2. These participants were matched by age and indication for IVF to participants having the long
GnRHa protocol
Sarhan 2012 This paper compared 3 GnRH analogues in long protocols
Sathanandan 1989 This comprised of long luteal GnRHa protocol with leuprolide in participants identified as having poor or
abnormal response in a previous stimulation cycle versus shortGnRHaprotocol with leuprolide in participants
undergoing their first cycle of treatment or who had had a satisfactory response in a previous cycle. Allocation
was not random, and participant groups were not similar
Smitz 1992 Quasi-randomisation (allocated to groups according to year of birth)
Smitz 1992a The method of allocation to short or long GnRHa protocol was not stated. Pregnancy was not the outcome
in this study because none of the participants had embryo transfer owing to complete failure of fertilisation
Stenbæk 2013 This trial compared a short antagonist versus long agonist protocol
Suganuma 1996 This paper reported pseudo-randomisation (alternate participants were allocated into the groups). Some
participants had cross-over of groups
Tanaka 2014 The was not an RCT
Tarin 1990 That study was a cytogenetic analysis of human unfertilised oocytes
Tarlatzis 1993 Although the study was designed to have random allocation, in practice the randomisation was incomplete as
it was done according to the stimulation protocol, the scheduling convenience, and the cost of the analogue
used
Tarlatzis 1994 Although the study was designed to have random allocation, in practice the randomisation was incomplete as
it was done according to the stimulation protocol, the scheduling convenience, and the cost of the analogue
used
Tehraninejad 2010 The paper compared daily doses versus Lupron Depot of GnRH in a long 21 protocol
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van de-Helder 1990b The paper compared GnRHa with no GnRHa
Wu 2012 Participants were assigned to 4 groups according to serum progesterone and oestradiol concentrations on the
day of HCG administration
Yang 1991 The paper compared GnRHa with no GnRHa
FSH-HMG: follicle stimulating hormone-human menopausal gonadotrophin.
GIFT: gamete intra-fallopian transfer.
GnRHa: gonadotrophin-releasing hormone agonists.
HCG: human chorionic gonadotrophin.
ICSI/ET: intracytoplasmic sperm injection/embryo transfer.
IVF: in vitro fertilisation.
RCT: randomised controlled trial.
s.c.: subcutaneously.
Characteristics of ongoing studies [ordered by study ID]
NCT01006954
Trial name or title Comparison of Micro Dose Gonadotropin-Releasing Hormone (GnRH) Agonist Flare up & Flare Protocol
in Poor Responders in Assisted Reproductive Technology (ART) Cycle
Methods Allocation: randomised
Endpoint Classification: efficacy Study
Intervention Model: parallel assignment
Masking: single blind (participant)
Primary purpose: treatment
Participants Inclusion criteria
• Poor responders
Exclusion criteria
• Male factor
• Myoma ≥ 6 cm
• 1 way ovary
• Tumour or cyst > 13 mm
• Age > 42
Interventions 1. Microflare and flare up protocols
Outcomes • Primary outcome measure: pregnancy rate
• Secondary outcome measures: cycle cancellation rates, number of oocytes generated, number of
embryos generated, implantation rate
Starting date September 2008
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NCT01006954 (Continued)
Contact information Endocrinology and Female Infertility Department
Reproductive Medicine Research Centre
Royan Institute
Academic Center for Education, Culture and Research (ACECR)
Tehran
Islamic Republic of Iran
14114
Notes This study has been completed. No data were published
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D A T A A N D A N A L Y S E S
Comparison 1. Long versus short protocol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth/ongoing pregnancies 12 976 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.94, 1.81]
1.1 Live birth 4 295 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.85, 3.03]
1.2 Ongoing pregnancies 8 681 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.82, 1.78]
2 Clinical pregnancies 19 1582 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [1.18, 1.92]
2.1 Non-selected group 15 1350 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [1.07, 1.79]
2.2 Poor responders 4 232 Odds Ratio (M-H, Fixed, 95% CI) 3.12 [1.39, 7.02]
3 Number of oocytes 10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Non-selected group 6 512 Mean Difference (IV, Fixed, 95% CI) 2.47 [2.21, 2.72]
3.2 Poor responders 4 227 Mean Difference (IV, Fixed, 95% CI) 1.40 [0.75, 2.06]
4 Dose of gonadotrophins 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Non-selected group 4 439 Mean Difference (IV, Fixed, 95% CI) 15.64 [14.05, 17.22]
4.2 Poor responders 4 227 Mean Difference (IV, Fixed, 95% CI) 7.07 [3.06, 11.08]
5 Cycle cancellation 11 1026 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.59, 1.55]
5.1 Non-selected group 7 799 Odds Ratio (M-H, Fixed, 95% CI) 1.73 [0.92, 3.23]
5.2 Poor responders 4 227 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.12, 0.76]
Comparison 2. Long protocol versus ultrashort protocol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Clinical pregnancies 2 230 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.80, 3.06]
3 Number of oocytes 2 230 Mean Difference (IV, Fixed, 95% CI) 0.53 [-0.61, 1.66]
4 Dose of gonadotrophins 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Cycle cancellation 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Short versus ultrashort protocol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Clinical pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Number of oocytes 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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4 Dose of gonadotrophins 1 82 Mean Difference (IV, Fixed, 95% CI) -13.85 [-21.49, -6.
21]
5 Cycle cancellation 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Long protocol (luteal versus follicular)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Clinical pregnancies 5 750 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.76, 1.47]
3 Number of oocytes 4 527 Mean Difference (IV, Fixed, 95% CI) -1.29 [-1.86, -0.71]
4 Dose of gonadotrophins 4 527 Mean Difference (IV, Fixed, 95% CI) 1.12 [-0.73, 2.97]
5 Cycle cancellation 2 267 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.35, 6.01]
Comparison 5. Long protocol (continued GnRHa versus stop GnRHa)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
3 290 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.42, 1.33]
1.1 Live birth 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Ongoing pregnancies 3 290 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.42, 1.33]
2 Clinical pregnancies 4 360 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.51, 1.41]
3 Number of oocytes 4 360 Mean Difference (IV, Fixed, 95% CI) -0.26 [-1.29, 0.78]
4 Dose of gonadotrophins 4 360 Mean Difference (IV, Fixed, 95% CI) -0.14 [-2.35, 2.08]
5 Cycle cancellation 3 264 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.56, 3.56]
6 Other outcomes - OHSS 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 6. Long protocol (continued same versus reduced dose GnRHa)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Clinical pregnancies 4 407 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.68, 1.52]
3 Number of oocytes 3 275 Mean Difference (IV, Fixed, 95% CI) 1.03 [-0.04, 2.10]
4 Dose of gonadotrophins 2 228 Mean Difference (IV, Fixed, 95% CI) 0.98 [-1.72, 3.69]
5 Cycle cancellation 2 228 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.32]
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Comparison 7. Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Clinical pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Number of oocytes 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Dose of gonadotrophins 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Cycle cancellation 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 8. Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Clinical pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Number of oocytes 1 85 Mean Difference (IV, Fixed, 95% CI) 0.12 [-1.90, 2.14]
4 Dose of gonadotrophins 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Cycle cancellation 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Other outcomes 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Miscarriages 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 OHSS 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 9. Short versus stop short protocol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth and ongoing
pregnancies
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Clinical pregnancies 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Number of oocytes 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Dose of gonadotrophins 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Cycle cancellation 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Long versus short protocol, Outcome 1 Live birth/ongoing pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 1 Long versus short protocol
Outcome: 1 Live birth/ongoing pregnancies
Study or subgroup long protocol short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Live birth
Acharya 1992 4/43 3/44 4.3 % 1.40 [ 0.29, 6.67 ]
Chatillon-Boissier 2012 2/22 3/22 4.4 % 0.63 [ 0.10, 4.22 ]
San Roman 1992 6/26 1/29 1.2 % 8.40 [ 0.94, 75.31 ]
Ye 2001 17/55 13/54 14.6 % 1.41 [ 0.61, 3.29 ]
Subtotal (95% CI) 146 149 24.5 % 1.60 [ 0.85, 3.03 ]
Total events: 29 (long protocol), 20 (short protocol)
Heterogeneity: Chi2 = 3.23, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Ongoing pregnancies
Dirnfeld 1991 6/28 1/26 1.3 % 6.82 [ 0.76, 61.12 ]
Foulot 1988 9/50 7/50 9.3 % 1.35 [ 0.46, 3.96 ]
Frydman 1988 17/94 15/92 20.0 % 1.13 [ 0.53, 2.43 ]
Loumaye 1989 2/9 1/9 1.3 % 2.29 [ 0.17, 30.96 ]
Sunkara 2014 3/37 3/37 4.4 % 1.00 [ 0.19, 5.31 ]
van de-Helder 1990 12/50 10/51 12.1 % 1.29 [ 0.50, 3.34 ]
Yang 1996 5/30 7/30 9.4 % 0.66 [ 0.18, 2.36 ]
Zhang 2009 20/44 20/44 17.6 % 1.00 [ 0.43, 2.31 ]
Subtotal (95% CI) 342 339 75.5 % 1.21 [ 0.82, 1.78 ]
Total events: 74 (long protocol), 64 (short protocol)
Heterogeneity: Chi2 = 3.82, df = 7 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Total (95% CI) 488 488 100.0 % 1.30 [ 0.94, 1.81 ]
Total events: 103 (long protocol), 84 (short protocol)
Heterogeneity: Chi2 = 7.45, df = 11 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
favours short protocol favours long protocol
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Analysis 1.2. Comparison 1 Long versus short protocol, Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 1 Long versus short protocol
Outcome: 2 Clinical pregnancies
Study or subgroup long protocol short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Non-selected group
Acharya 1992 4/43 3/44 2.6 % 1.40 [ 0.29, 6.67 ]
De Placido 1991 6/27 5/24 3.9 % 1.09 [ 0.28, 4.14 ]
Fenichel 1988 1/10 3/10 2.6 % 0.26 [ 0.02, 3.06 ]
Foulot 1988 10/50 12/50 9.1 % 0.79 [ 0.31, 2.05 ]
Frydman 1988 22/94 16/92 11.8 % 1.45 [ 0.71, 2.98 ]
Hazout 1993 18/96 15/86 12.2 % 1.09 [ 0.51, 2.33 ]
Hedon 1988 18/56 5/56 3.2 % 4.83 [ 1.65, 14.17 ]
Loumaye 1989 2/9 1/9 0.7 % 2.29 [ 0.17, 30.96 ]
San Roman 1992 6/26 4/29 2.8 % 1.88 [ 0.46, 7.57 ]
Tan 1992 9/46 4/45 3.1 % 2.49 [ 0.71, 8.78 ]
Tasdemir 1995 20/45 7/45 3.7 % 4.34 [ 1.60, 11.78 ]
van de-Helder 1990 9/50 14/51 10.8 % 0.58 [ 0.22, 1.50 ]
Yang 1996 8/30 10/30 7.0 % 0.73 [ 0.24, 2.21 ]
Ye 2001 20/55 17/54 10.4 % 1.24 [ 0.56, 2.75 ]
Zhang 2009 24/44 21/44 9.1 % 1.31 [ 0.57, 3.04 ]
Subtotal (95% CI) 681 669 93.1 % 1.38 [ 1.07, 1.79 ]
Total events: 177 (long protocol), 137 (short protocol)
Heterogeneity: Chi2 = 19.62, df = 14 (P = 0.14); I2 =29%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Poor responders
Chatillon-Boissier 2012 4/22 3/22 2.3 % 1.41 [ 0.28, 7.18 ]
Dirnfeld 1991 8/28 2/26 1.4 % 4.80 [ 0.91, 25.23 ]
Sunkara 2014 6/37 3/37 2.4 % 2.19 [ 0.50, 9.53 ]
Weissman 2003 7/31 1/29 0.8 % 8.17 [ 0.94, 71.17 ]
Subtotal (95% CI) 118 114 6.9 % 3.12 [ 1.39, 7.02 ]
Total events: 25 (long protocol), 9 (short protocol)
Heterogeneity: Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
0.005 0.1 1 10 200
favours short protocol favours long protocol
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(. . . Continued)
Study or subgroup long protocol short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.75 (P = 0.0060)
Total (95% CI) 799 783 100.0 % 1.50 [ 1.18, 1.92 ]
Total events: 202 (long protocol), 146 (short protocol)
Heterogeneity: Chi2 = 24.63, df = 18 (P = 0.14); I2 =27%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Chi2 = 3.50, df = 1 (P = 0.06), I2 =71%
0.005 0.1 1 10 200
favours short protocol favours long protocol
Analysis 1.3. Comparison 1 Long versus short protocol, Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 1 Long versus short protocol
Outcome: 3 Number of oocytes
Study or subgroup long protocol short protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Non-selected group
Hazout 1993 96 10.7 (1.2) 86 7.3 (1) 65.3 % 3.40 [ 3.08, 3.72 ]
Loumaye 1989 9 10.4 (5.4) 9 11.2 (7.8) 0.2 % -0.80 [ -7.00, 5.40 ]
San Roman 1992 26 9 (5.5) 29 7.1 (5.3) 0.8 % 1.90 [ -0.96, 4.76 ]
Yang 1996 30 6.63 (0.9) 30 5.96 (0.91) 31.8 % 0.67 [ 0.21, 1.13 ]
Ye 2001 55 13.4 (6.3) 54 11.9 (6.1) 1.2 % 1.50 [ -0.83, 3.83 ]
Zhang 2009 44 15.14 (7.77) 44 15.07 (7.16) 0.7 % 0.07 [ -3.05, 3.19 ]
Subtotal (95% CI) 260 252 100.0 % 2.47 [ 2.21, 2.72 ]
Heterogeneity: Chi2 = 95.98, df = 5 (P<0.00001); I2 =95%
Test for overall effect: Z = 18.70 (P < 0.00001)
2 Poor responders
Chatillon-Boissier 2012 20 6.74 (2.73) 19 6.38 (4.26) 8.5 % 0.36 [ -1.90, 2.62 ]
Dirnfeld 1991 28 7 (3.1) 26 5.6 (1.4) 26.9 % 1.40 [ 0.13, 2.67 ]
-4 -2 0 2 4
favours short protocol favours long protocol
(Continued . . . )
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Study or subgroup long protocol short protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sunkara 2014 37 4.42 (3.06) 37 2.71 (1.61) 34.8 % 1.71 [ 0.60, 2.82 ]
Weissman 2003 31 4.42 (2.6) 29 3.07 (2.15) 29.8 % 1.35 [ 0.15, 2.55 ]
Subtotal (95% CI) 116 111 100.0 % 1.40 [ 0.75, 2.06 ]
Heterogeneity: Chi2 = 1.12, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.19 (P = 0.000028)
Test for subgroup differences: Chi2 = 8.66, df = 1 (P = 0.00), I2 =88%
-4 -2 0 2 4
favours short protocol favours long protocol
Analysis 1.4. Comparison 1 Long versus short protocol, Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 1 Long versus short protocol
Outcome: 4 Dose of gonadotrophins
Study or subgroup long protocol short protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Non-selected group
Hazout 1993 96 42.5 (9.75) 86 24 (7) 42.0 % 18.50 [ 16.05, 20.95 ]
Yang 1996 30 50.59 (10.79) 30 21.48 (3.69) 15.1 % 29.11 [ 25.03, 33.19 ]
Ye 2001 55 28 (8.6) 54 23.4 (8.7) 23.9 % 4.60 [ 1.35, 7.85 ]
Zhang 2009 44 35.9 (9.9) 44 23.46 (7.35) 19.0 % 12.44 [ 8.80, 16.08 ]
Subtotal (95% CI) 225 214 100.0 % 15.64 [ 14.05, 17.22 ]
Heterogeneity: Chi2 = 94.44, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 19.31 (P < 0.00001)
2 Poor responders
Chatillon-Boissier 2012 20 49.55 (11.69) 19 42.63 (13.37) 25.8 % 6.92 [ -0.98, 14.82 ]
Dirnfeld 1991 28 22 (10.6) 26 16 (16) 30.3 % 6.00 [ -1.30, 13.30 ]
Sunkara 2014 37 73.87 (16.3) 37 64.25 (15.75) 30.2 % 9.62 [ 2.32, 16.92 ]
-20 -10 0 10 20
favours long protocol favours short protocol
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Study or subgroup long protocol short protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Weissman 2003 31 66.9 (14.6) 29 62.8 (26.2) 13.7 % 4.10 [ -6.73, 14.93 ]
Subtotal (95% CI) 116 111 100.0 % 7.07 [ 3.06, 11.08 ]
Heterogeneity: Chi2 = 0.84, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00056)
Test for subgroup differences: Chi2 = 15.14, df = 1 (P = 0.00), I2 =93%
-20 -10 0 10 20
favours long protocol favours short protocol
Analysis 1.5. Comparison 1 Long versus short protocol, Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 1 Long versus short protocol
Outcome: 5 Cycle cancellation
Study or subgroup long protocol short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Non-selected group
Acharya 1992 2/43 4/44 11.2 % 0.49 [ 0.08, 2.81 ]
Foulot 1988 5/50 4/50 10.7 % 1.28 [ 0.32, 5.07 ]
Frydman 1988 4/94 1/92 2.9 % 4.04 [ 0.44, 36.89 ]
Hazout 1993 4/96 2/86 6.0 % 1.83 [ 0.33, 10.23 ]
San Roman 1992 2/26 3/29 7.8 % 0.72 [ 0.11, 4.70 ]
van de-Helder 1990 11/50 3/51 6.9 % 4.51 [ 1.18, 17.32 ]
Zhang 2009 0/44 0/44 Not estimable
Subtotal (95% CI) 403 396 45.6 % 1.73 [ 0.92, 3.23 ]
Total events: 28 (long protocol), 17 (short protocol)
Heterogeneity: Chi2 = 5.55, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.71 (P = 0.088)
2 Poor responders
0.01 0.1 1 10 100
favours long protocol favours short protocol
(Continued . . . )
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(. . . Continued)
Study or subgroup long protocol short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chatillon-Boissier 2012 1/20 3/19 8.7 % 0.28 [ 0.03, 2.97 ]
Dirnfeld 1991 2/28 10/26 28.7 % 0.12 [ 0.02, 0.64 ]
Sunkara 2014 3/37 4/37 11.0 % 0.73 [ 0.15, 3.50 ]
Weissman 2003 1/31 2/29 6.0 % 0.45 [ 0.04, 5.25 ]
Subtotal (95% CI) 116 111 54.4 % 0.31 [ 0.12, 0.76 ]
Total events: 7 (long protocol), 19 (short protocol)
Heterogeneity: Chi2 = 2.45, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.011)
Total (95% CI) 519 507 100.0 % 0.95 [ 0.59, 1.55 ]
Total events: 35 (long protocol), 36 (short protocol)
Heterogeneity: Chi2 = 15.63, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 9.46, df = 1 (P = 0.00), I2 =89%
0.01 0.1 1 10 100
favours long protocol favours short protocol
Analysis 2.1. Comparison 2 Long protocol versus ultrashort protocol, Outcome 1 Live birth and ongoing
pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 2 Long protocol versus ultrashort protocol
Outcome: 1 Live birth and ongoing pregnancies
Study or subgroup long protocol ultrashort protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kingsland 1992 15/76 9/74 1.78 [ 0.72, 4.36 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 15 (long protocol), 9 (ultrashort protocol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
favours u/short protocol favours long protocol
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Analysis 2.2. Comparison 2 Long protocol versus ultrashort protocol, Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 2 Long protocol versus ultrashort protocol
Outcome: 2 Clinical pregnancies
Study or subgroup long protocol ultrashort protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 1992 7/37 8/43 43.7 % 1.02 [ 0.33, 3.15 ]
Kingsland 1992 18/76 10/74 56.3 % 1.99 [ 0.85, 4.65 ]
Total (95% CI) 113 117 100.0 % 1.56 [ 0.80, 3.06 ]
Total events: 25 (long protocol), 18 (ultrashort protocol)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours u/short protocol favours long protocol
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Analysis 2.3. Comparison 2 Long protocol versus ultrashort protocol, Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 2 Long protocol versus ultrashort protocol
Outcome: 3 Number of oocytes
Study or subgroup long protocol ultrashort protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 1992 37 7.9 (4.7) 43 8.8 (4.2) 33.3 % -0.90 [ -2.87, 1.07 ]
Kingsland 1992 76 7.59 (4) 74 6.35 (4.66) 66.7 % 1.24 [ -0.15, 2.63 ]
Total (95% CI) 113 117 100.0 % 0.53 [ -0.61, 1.66 ]
Heterogeneity: Chi2 = 3.03, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours u/short protocol favours long protocol
Analysis 2.4. Comparison 2 Long protocol versus ultrashort protocol, Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 2 Long protocol versus ultrashort protocol
Outcome: 4 Dose of gonadotrophins
Study or subgroup long protocol ultrashort protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 1992 37 23.5 (7.1) 43 22.4 (6) 1.10 [ -1.81, 4.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
favours long protocol favours u/short protocol
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Analysis 2.5. Comparison 2 Long protocol versus ultrashort protocol, Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 2 Long protocol versus ultrashort protocol
Outcome: 5 Cycle cancellation
Study or subgroup long protocol ultrashort protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kingsland 1992 9/76 8/74 1.11 [ 0.40, 3.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 9 (long protocol), 8 (ultrashort protocol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
favours long protocol favours u/short protocol
Analysis 3.2. Comparison 3 Short versus ultrashort protocol, Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 3 Short versus ultrashort protocol
Outcome: 2 Clinical pregnancies
Study or subgroup short agonist ultrashort agonist Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berker 2010 10/41 8/41 1.33 [ 0.47, 3.81 ]
0.01 0.1 1 10 100
favours u/short protocol favours short protocol
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Analysis 3.3. Comparison 3 Short versus ultrashort protocol, Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 3 Short versus ultrashort protocol
Outcome: 3 Number of oocytes
Study or subgroup short ultrashort
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Berker 2010 41 8.52 (6.38) 41 7.82 (5.24) 0.70 [ -1.83, 3.23 ]
-50 -25 0 25 50
favours u/short protocol favours short protocol
Analysis 3.4. Comparison 3 Short versus ultrashort protocol, Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 3 Short versus ultrashort protocol
Outcome: 4 Dose of gonadotrophins
Study or subgroup short ultrashort
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Berker 2010 41 31.02 (12.35) 41 44.87 (21.7) 100.0 % -13.85 [ -21.49, -6.21 ]
Total (95% CI) 41 41 100.0 % -13.85 [ -21.49, -6.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
favours short protocol favours u/short protocol
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Analysis 3.5. Comparison 3 Short versus ultrashort protocol, Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 3 Short versus ultrashort protocol
Outcome: 5 Cycle cancellation
Study or subgroup short agonist ultrashort agonist Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berker 2010 2/41 2/41 1.00 [ 0.13, 7.46 ]
0.01 0.1 1 10 100
favours short protocol favours u/short protocol
Analysis 4.1. Comparison 4 Long protocol (luteal versus follicular), Outcome 1 Live birth and ongoing
pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 4 Long protocol (luteal versus follicular)
Outcome: 1 Live birth and ongoing pregnancies
Study or subgroup luteal start follicular start Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Urbancsek 1996 17/96 13/127 1.89 [ 0.87, 4.10 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 17 (luteal start), 13 (follicular start)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours follicular start favours luteal start
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Analysis 4.2. Comparison 4 Long protocol (luteal versus follicular), Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 4 Long protocol (luteal versus follicular)
Outcome: 2 Clinical pregnancies
Study or subgroup luteal start follicular start Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondaveeti-Gordon 1996 12/48 9/38 11.2 % 1.07 [ 0.40, 2.90 ]
Pellicer 1989 4/29 6/15 10.1 % 0.24 [ 0.05, 1.05 ]
Ron-El 1990 24/108 29/108 33.5 % 0.78 [ 0.42, 1.45 ]
Sarhan 2013 38/115 21/66 26.5 % 1.06 [ 0.55, 2.02 ]
Urbancsek 1996 26/96 20/127 18.6 % 1.99 [ 1.03, 3.83 ]
Total (95% CI) 396 354 100.0 % 1.06 [ 0.76, 1.47 ]
Total events: 104 (luteal start), 85 (follicular start)
Heterogeneity: Chi2 = 8.36, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours follicular start favours luteal start
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Analysis 4.3. Comparison 4 Long protocol (luteal versus follicular), Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 4 Long protocol (luteal versus follicular)
Outcome: 3 Number of oocytes
Study or subgroup luteal start follicular start
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kondaveeti-Gordon 1996 48 12 (8) 38 10.3 (7) 3.3 % 1.70 [ -1.47, 4.87 ]
Pellicer 1989 29 6.9 (1.1) 15 8.7 (1.1) 70.0 % -1.80 [ -2.49, -1.11 ]
Ron-El 1990 108 7.1 (4.9) 108 7.9 (4.4) 21.3 % -0.80 [ -2.04, 0.44 ]
Sarhan 2013 115 13.3 (9.3) 66 11.7 (7.4) 5.4 % 1.60 [ -0.87, 4.07 ]
Total (95% CI) 300 227 100.0 % -1.29 [ -1.86, -0.71 ]
Heterogeneity: Chi2 = 11.41, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
favours follicular start favours luteal start
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Analysis 4.4. Comparison 4 Long protocol (luteal versus follicular), Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 4 Long protocol (luteal versus follicular)
Outcome: 4 Dose of gonadotrophins
Study or subgroup luteal start follicular start
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kondaveeti-Gordon 1996 48 62 (9.4) 38 58 (10.1) 19.6 % 4.00 [ -0.17, 8.17 ]
Pellicer 1989 29 34.6 (10.23) 15 36.1 (8.9) 10.0 % -1.50 [ -7.34, 4.34 ]
Ron-El 1990 108 45 (15) 108 41.5 (13) 24.4 % 3.50 [ -0.24, 7.24 ]
Sarhan 2013 115 39.3 (9.5) 66 40.1 (8.7) 46.0 % -0.80 [ -3.52, 1.92 ]
Total (95% CI) 300 227 100.0 % 1.12 [ -0.73, 2.97 ]
Heterogeneity: Chi2 = 6.07, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
favours luteal start favours follicular start
Analysis 4.5. Comparison 4 Long protocol (luteal versus follicular), Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 4 Long protocol (luteal versus follicular)
Outcome: 5 Cycle cancellation
Study or subgroup luteal start follicular start Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kondaveeti-Gordon 1996 4/48 2/38 62.1 % 1.64 [ 0.28, 9.45 ]
Sarhan 2013 2/115 1/66 37.9 % 1.15 [ 0.10, 12.93 ]
Total (95% CI) 163 104 100.0 % 1.45 [ 0.35, 6.01 ]
Total events: 6 (luteal start), 3 (follicular start)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours follicular start favours luteal start
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Analysis 5.1. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 1 Live birth
and ongoing pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 1 Live birth and ongoing pregnancies
Study or subgroup continue GnRHa stop GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Live birth
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (continue GnRHa), 0 (stop GnRHa)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Ongoing pregnancies
Ding 2013 18/49 19/47 45.7 % 0.86 [ 0.38, 1.95 ]
Dirnfeld 1999 1/38 2/40 7.1 % 0.51 [ 0.04, 5.91 ]
Simons 2005 12/58 16/58 47.2 % 0.68 [ 0.29, 1.61 ]
Subtotal (95% CI) 145 145 100.0 % 0.75 [ 0.42, 1.33 ]
Total events: 31 (continue GnRHa), 37 (stop GnRHa)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 145 145 100.0 % 0.75 [ 0.42, 1.33 ]
Total events: 31 (continue GnRHa), 37 (stop GnRHa)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours stop GnRHa favours continue GnRHa
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Analysis 5.2. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 2 Clinical
pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 2 Clinical pregnancies
Study or subgroup continue GnRHa stop GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ding 2013 20/49 19/47 35.1 % 1.02 [ 0.45, 2.30 ]
Dirnfeld 1999 3/38 3/40 8.2 % 1.06 [ 0.20, 5.59 ]
Garcia-Velasco 2000 5/36 6/34 16.3 % 0.75 [ 0.21, 2.74 ]
Simons 2005 13/58 17/58 40.4 % 0.70 [ 0.30, 1.61 ]
Total (95% CI) 181 179 100.0 % 0.85 [ 0.51, 1.41 ]
Total events: 41 (continue GnRHa), 45 (stop GnRHa)
Heterogeneity: Chi2 = 0.50, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours stop GnRHa favours continue GnRHa
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Analysis 5.3. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 3 Number of
oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 3 Number of oocytes
Study or subgroup continue GnRHa stop GnRHa
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ding 2013 49 17 (4.5) 47 15.6 (4.3) 34.4 % 1.40 [ -0.36, 3.16 ]
Dirnfeld 1999 38 7.73 (6.18) 40 6.46 (4.11) 19.4 % 1.27 [ -1.07, 3.61 ]
Garcia-Velasco 2000 36 6.2 (4.2) 34 8.7 (5.2) 21.6 % -2.50 [ -4.72, -0.28 ]
Simons 2005 58 9.3 (5.4) 58 11.1 (6) 24.7 % -1.80 [ -3.88, 0.28 ]
Total (95% CI) 181 179 100.0 % -0.26 [ -1.29, 0.78 ]
Heterogeneity: Chi2 = 11.07, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours stop GnRHa favours continue GnRHa
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Analysis 5.4. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 4 Dose of
gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 4 Dose of gonadotrophins
Study or subgroup continue GnRHa stop GnRHa
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ding 2013 49 21.9 (6) 47 21.9 (8.6) 55.3 % 0.0 [ -2.98, 2.98 ]
Dirnfeld 1999 38 42.6 (17.8) 40 46.7 (19.6) 7.1 % -4.10 [ -12.40, 4.20 ]
Garcia-Velasco 2000 36 68 (21) 34 56.6 (15.7) 6.5 % 11.40 [ 2.75, 20.05 ]
Simons 2005 58 35.3 (10.3) 58 37.2 (11.5) 31.1 % -1.90 [ -5.87, 2.07 ]
Total (95% CI) 181 179 100.0 % -0.14 [ -2.35, 2.08 ]
Heterogeneity: Chi2 = 8.47, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours continue GnRHa favours stop GnRHa
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Analysis 5.5. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 5 Cycle
cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 5 Cycle cancellation
Study or subgroup continue GnRHa stop GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dirnfeld 1999 8/38 1/40 10.1 % 10.40 [ 1.23, 87.75 ]
Garcia-Velasco 2000 1/36 2/34 26.3 % 0.46 [ 0.04, 5.29 ]
Simons 2005 2/58 5/58 63.5 % 0.38 [ 0.07, 2.04 ]
Total (95% CI) 132 132 100.0 % 1.41 [ 0.56, 3.56 ]
Total events: 11 (continue GnRHa), 8 (stop GnRHa)
Heterogeneity: Chi2 = 6.54, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours continue GnRHa favours stop GnRHa
Analysis 5.6. Comparison 5 Long protocol (continued GnRHa versus stop GnRHa), Outcome 6 Other
outcomes - OHSS.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 5 Long protocol (continued GnRHa versus stop GnRHa)
Outcome: 6 Other outcomes - OHSS
Study or subgroup continue GnRHa stop GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ding 2013 1/49 2/47 0.47 [ 0.04, 5.35 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (continue GnRHa), 2 (stop GnRHa)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
favours continue GnRHa favours stop GnRHa
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Analysis 6.2. Comparison 6 Long protocol (continued same versus reduced dose GnRHa), Outcome 2
Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 6 Long protocol (continued same versus reduced dose GnRHa)
Outcome: 2 Clinical pregnancies
Study or subgroup
continue
same dose
GnRHa
decreased
dose of
GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dal Prato 2001 24/66 22/66 29.6 % 1.14 [ 0.56, 2.34 ]
Ding 2013 20/49 19/47 24.3 % 1.02 [ 0.45, 2.30 ]
F bregues 2005 27/68 28/69 35.5 % 0.96 [ 0.49, 1.91 ]
Simon 1994 7/22 7/20 10.6 % 0.87 [ 0.24, 3.13 ]
Total (95% CI) 205 202 100.0 % 1.02 [ 0.68, 1.52 ]
Total events: 78 (continue same dose GnRHa), 76 (decreased dose of GnRHa)
Heterogeneity: Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.92)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
favours decreased dose GnRHa favours continue same dose GnRHa
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Analysis 6.3. Comparison 6 Long protocol (continued same versus reduced dose GnRHa), Outcome 3
Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 6 Long protocol (continued same versus reduced dose GnRHa)
Outcome: 3 Number of oocytes
Study or subgroup
continue
same dose
GnRHa
decreased
dose of
GnRHa
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ding 2013 49 17 (4.5) 47 15.6 (4.3) 36.7 % 1.40 [ -0.36, 3.16 ]
F bregues 2005 68 10.4 (5.7) 69 9.5 (2.49) 52.2 % 0.90 [ -0.58, 2.38 ]
Simon 1994 22 13.3 (4.69) 20 12.9 (5.81) 11.0 % 0.40 [ -2.81, 3.61 ]
Total (95% CI) 139 136 100.0 % 1.03 [ -0.04, 2.10 ]
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours decreased dose GnRHa favours same dose GnRHa
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Analysis 6.4. Comparison 6 Long protocol (continued same versus reduced dose GnRHa), Outcome 4 Dose
of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 6 Long protocol (continued same versus reduced dose GnRHa)
Outcome: 4 Dose of gonadotrophins
Study or subgroup
continue
same dose
GnRHa
decreased
dose of
GnRHa
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dal Prato 2001 66 46.6 (25.3) 66 41 (8.6) 17.6 % 5.60 [ -0.85, 12.05 ]
Ding 2013 49 21.9 (6) 47 21.9 (8.6) 82.4 % 0.0 [ -2.98, 2.98 ]
Total (95% CI) 115 113 100.0 % 0.98 [ -1.72, 3.69 ]
Heterogeneity: Chi2 = 2.39, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
favours same dose favours decreased dose
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Analysis 6.5. Comparison 6 Long protocol (continued same versus reduced dose GnRHa), Outcome 5 Cycle
cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 6 Long protocol (continued same versus reduced dose GnRHa)
Outcome: 5 Cycle cancellation
Study or subgroup
continue
same dose
GnRHa
decreased
dose of
GnRHa Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dal Prato 2001 2/66 2/66 100.0 % 1.00 [ 0.14, 7.32 ]
Ding 2013 0/49 0/47 Not estimable
Total (95% CI) 115 113 100.0 % 1.00 [ 0.14, 7.32 ]
Total events: 2 (continue same dose GnRHa), 2 (decreased dose of GnRHa)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours same dose GnRHa favours decreased dose
Analysis 7.1. Comparison 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG),
Outcome 1 Live birth and ongoing pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome: 1 Live birth and ongoing pregnancies
Study or subgroup GnRHa until hCG
GnRHa
extend 12d
after hC Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Isikoglu 2007 32/91 34/90 0.89 [ 0.49, 1.64 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 32 (GnRHa until hCG), 34 (GnRHa extend 12d after hC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours GnRHa 12 days after ET favours GnRHa until HCG
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Analysis 7.2. Comparison 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG),
Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome: 2 Clinical pregnancies
Study or subgroup GnRHa until HCG
GnRHa extend
12d after HCG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Isikoglu 2007 45/91 44/90 1.02 [ 0.57, 1.83 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 45 (GnRHa until HCG), 44 (GnRHa extend 12d after HCG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours GnRHa 12 days after ET favours GnRHa until HCG
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Analysis 7.3. Comparison 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG),
Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome: 3 Number of oocytes
Study or subgroup GnRHa until HCG
GnRHa extend
12d after HCG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Isikoglu 2007 91 12.4 (7.8) 90 13.3 (6.9) -0.90 [ -3.04, 1.24 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
favours GnRHa 12 days after ET favours GnRHa until HCG
Analysis 7.4. Comparison 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG),
Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome: 4 Dose of gonadotrophins
Study or subgroup GnRHa until HCG
GnRHa
extend 12d
after HC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Isikoglu 2007 91 55.9 (11.35) 90 53.1 (11.62) 2.80 [ -0.55, 6.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
favours GnRHa until HCG favours GnRHa12days after
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Analysis 7.5. Comparison 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG),
Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 7 Long protocol (GnRHa until HCG versus extended GnRHa 12 days after HCG)
Outcome: 5 Cycle cancellation
Study or subgroup GnRHa until HCG
GnRHa
extend 12d
after HC Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Isikoglu 2007 3/91 2/90 1.50 [ 0.24, 9.20 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (GnRHa until HCG), 2 (GnRHa extend 12d after HC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours GnRHa until HCG favours GnRHa12daysafter
Analysis 8.1. Comparison 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation),
Outcome 1 Live birth and ongoing pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome: 1 Live birth and ongoing pregnancies
Study or subgroup GnRHa for 3 weeks GnRHa for 3 weeks Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lin 2013 20/44 20/41 0.88 [ 0.37, 2.05 ]
0.01 0.1 1 10 100
favours 3 weeks favours 2 weeks
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Analysis 8.2. Comparison 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation),
Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome: 2 Clinical pregnancies
Study or subgroup GnRHa for 2 weeks GnRHa for 3 weeks Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lin 2013 25/44 24/41 0.93 [ 0.39, 2.21 ]
0.01 0.1 1 10 100
favours 3 weeks favours 2 weeks
Analysis 8.3. Comparison 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation),
Outcome 3 Number of oocytes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome: 3 Number of oocytes
Study or subgroup GnRHa for 2 weeks GnRHa for 3 weeks
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2013 44 12.27 (5.48) 41 12.15 (3.97) 100.0 % 0.12 [ -1.90, 2.14 ]
Total (95% CI) 44 41 100.0 % 0.12 [ -1.90, 2.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
favours 3 weeks favours 2 weeks
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Analysis 8.4. Comparison 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation),
Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome: 4 Dose of gonadotrophins
Study or subgroup GnRHa for 2 weeks GnRHa for 3 weeks
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2013 44 1753.6 (644) 41 1546.6 (538) 207.00 [ -44.65, 458.65 ]
-500 -250 0 250 500
favours 2 weeks favours 3 weeks
Analysis 8.6. Comparison 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation),
Outcome 6 Other outcomes.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 8 Long protocol (GnRHa for 2 weeks versus 3 weeks before stimulation)
Outcome: 6 Other outcomes
Study or subgroup GnRHa for 2 weeks GnRHa for 3 weeks Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Miscarriages
Lin 2013 3/44 3/41 0.93 [ 0.18, 4.87 ]
2 OHSS
Lin 2013 1/44 1/41 0.93 [ 0.06, 15.37 ]
0.05 0.2 1 5 20
favours 2 weeks favours 3 weeks
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Analysis 9.2. Comparison 9 Short versus stop short protocol, Outcome 2 Clinical pregnancies.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 9 Short versus stop short protocol
Outcome: 2 Clinical pregnancies
Study or subgroup short protocol stop short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cedrin-Durnerin 2000 17/115 26/115 0.59 [ 0.30, 1.17 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 17 (short protocol), 26 (stop short protocol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours stop short favours short
Analysis 9.4. Comparison 9 Short versus stop short protocol, Outcome 4 Dose of gonadotrophins.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 9 Short versus stop short protocol
Outcome: 4 Dose of gonadotrophins
Study or subgroup short protocol stop short protocol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cedrin-Durnerin 2000 115 30.2 (11.2) 115 35.4 (11.3) -5.20 [ -8.11, -2.29 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours short favours stop short
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Analysis 9.5. Comparison 9 Short versus stop short protocol, Outcome 5 Cycle cancellation.
Review: Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction
Comparison: 9 Short versus stop short protocol
Outcome: 5 Cycle cancellation
Study or subgroup short protocol stop short protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cedrin-Durnerin 2000 13/115 17/115 0.73 [ 0.34, 1.59 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 13 (short protocol), 17 (stop short protocol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours short favours stop short
A P P E N D I C E S
Appendix 1. Menstrual Disorders and Subfertility database search
Search strategy for SD265 09.04.14:
Keywords CONTAINS “IVF” or “ICSI” or “in-vitro fertilisation ” or “in-vitro fertilisation procedure” or “in vitro fertilization” or
“intracytoplasmic sperm injection” or “intracytoplasmic morphologically selected sperm injection” or “controlled ovarian hyperstim-
ulation” or “controlled ovarian stimulation” or“COH” or“embryo transfer” or“ovarian hyperstimulation”or “ovarian stimulation” or
Title CONTAINS “IVF” or “ICSI” or “in-vitro fertilisation ” or “in-vitro fertilisation procedure” or “in vitro fertilization” or “intra-
cytoplasmic sperm injection” or “intracytoplasmic morphologically selected sperm injection”or “controlled ovarian hyperstimulation”
or “controlled ovarian stimulation” or“COH” or“embryo transfer” or“ovarian hyperstimulation”or “ovarian stimulation”
AND
Keywords CONTAINS “Gonadorelin” or “Gonadotrophin releasing agonist”or “Gonadotrophin
releasing hormones”or “gonadotropin releasing hormone agonist” or “Goserelin” or “goserelin acetate” or “goserelin pretreatment”
or“Gosereline ”or “buserelin”or “busereline”or“leuprolide ”or“leuprolin”or“leuprorelin”or“nafarelin”or“triptorelin”or“Lupron”or “Zo-
ladex”or“deslorelin”or “GnRH agonist”or “GnRH a”or“GnRH agonists”or“GnRHa”or“GnRH analog”or“GnRH analogue”or“GnRH
analogues”or“Luteinising hormone releasing hormone”or“luteinizing hormone supplementation”or“Lutenising hormone releasing
hormone”or“menotropin”or“menotrophin”or“human menopausal gonadotrophin”or“human menopausal gonadotrophins”or “human
menopausal gonadotrophins”or Title CONTAINS “Gonadorelin” or “Gonadotrophin releasing agonist”or “Gonadotrophin releasing
hormones”or “gonadotropin releasing hormone agonist”
AND
KeywordsCONTAINS “desensitisation vs flareup”or“long agonist protocol”or “long-longprotocol”or “longprotocol”or“long-termGn-
RHa treatment”or“long v short protocol”or“short interval”or“short protocol”or“ultra long protocol”or“ultra-short protocol”or“reduced
dose”or“down regulation”or“follicular phase”or“high dose”or“high dose protocol”or“stop protocol”or“prolonged stimulation”or“day
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7”or “continuous”or“early v late”or“early versus late”or“daily”or or“dosage”or“dose”or “long-term”or“flare-up”or “flare-up GnRH ag-
onist”or“flare-up protocol”or“Protocols”or“dose-response study”or“dosing regimen
Appendix 2. CENTRAL search
EBM Reviews - Cochrane Central Register of Controlled Trials <March 2015>
Search Strategy:
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or exp gamete intrafallopian transfer/ or
exp in vitro oocyte maturation techniques/ (1765)
2 embryo transfer.tw. (1066)
3 in vitro fertili?ation.tw. (1571)
4 intracytoplasmic sperm injection$.tw. (518)
5 (ivf or icsi).tw. (2756)
6 exp Infertility, Female/ (930)
7 exp Primary Ovarian Insufficiency/ (68)
8 exp Infertility/ (1664)
9 (ovar$ adj2 stimulat$).tw. (976)
10 (ovar$ adj2 hyperstimulat$).tw. (675)
11 COH.tw. (162)
12 or/1-11 (5354)
13 exp gonadotropin-releasing hormone/ or exp buserelin/ or exp goserelin/ or exp leuprolide/ or exp nafarelin/ or exp triptorelin
pamoate/ (1885)
14 gonadotropin-releasing hormone$.tw. (835)
15 (buserelin or goserelin or leuprolide or nafarelin or triptorelin).tw. (1330)
16 (Lupron or Suprefact or Suprecor).tw. (45)
17 (histrelin or Supprelin).tw. (1)
18 (Zoladex or deslorelin).tw. (236)
19 (Suprelorin or Ovuplant).tw. (0)
20 Synarel.tw. (3)
21 GnRHa.tw. (236)
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22 GnRH-a.tw. (1393)
23 GnRH agonist$.tw. (796)
24 GnRH analog$.tw. (313)
25 luteinizing hormone releasing agonist$.tw. (1)
26 exp Menotropins/ (358)
27 human menopausal gonadotropin$.tw. (239)
28 or/13-27 (3595)
29 desensiti?ation.tw. (1004)
30 (long adj2 protocol).tw. (335)
31 (short adj2 protocol).tw. (122)
32 (ultra short adj2 protocol).tw. (3)
33 (long adj2 follicular).tw. (10)
34 (ultrashort adj2 protocol).tw. (3)
35 reduced dos$.tw. (840)
36 down regulat$.tw. (923)
37 downregulat$.tw. (587)
38 (follicular adj5 luteal).tw. (293)
39 high dose$.tw. (13920)
40 stop versus non stop.tw. (1)
41 prolonged protocol.tw. (1)
42 7 day.tw. (3291)
43 continu$ versus stop$.tw. (2)
44 short acting.tw. (1380)
45 early cessation.tw. (36)
46 early follicular.tw. (198)
47 different phase$.tw. (173)
48 daily.tw. (78531)
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49 long acting.tw. (3713)
50 long luteal.tw. (13)
51 desensiti?e.tw. (31)
52 suppression.tw. (7910)
53 suppress.tw. (1966)
54 (inhibition or inhibit).tw. (16876)
55 (long adj2 protocol$).tw. (375)
56 (short adj2 protocol$).tw. (142)
57 or/29-56 (119095)
58 12 and 28 and 57 (722)
Appendix 3. MEDLINE search
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or exp gamete intrafallopian transfer/ or
exp in vitro oocyte maturation techniques/ (32710)
2 embryo transfer.tw. (7668)
3 in vitro fertili?ation.tw. (16760)
4 intracytoplasmic sperm injection$.tw. (4912)
5 (ivf or icsi).tw. (18836)
6 exp Infertility, Female/ (23368)
7 exp Primary Ovarian Insufficiency/ (1673)
8 exp Infertility/ (52626)
9 (ovar$ adj2 stimulat$).tw. (4982)
10 (ovar$ adj2 hyperstimulat$).tw. (3842)
11 COH.tw. (1130)
12 or/1-11 (89231)
13 exp gonadotropin-releasing hormone/ or exp buserelin/ or exp goserelin/ or exp leuprolide/ or exp nafarelin/ or exp triptorelin
pamoate/ (28527)
14 gonadotropin-releasing hormone$.tw. (11008)
15 (buserelin or goserelin or leuprolide or nafarelin or triptorelin).tw. (4078)
16 (Lupron or Suprefact or Suprecor).tw. (168)
17 (histrelin or Supprelin).tw. (46)
18 (Zoladex or deslorelin).tw. (560)
19 (Suprelorin or Ovuplant).tw. (22)
20 Synarel.tw. (12)
21 GnRHa.tw. (1094)
22 GnRH-a.tw. (900)
23 GnRH agonist$.tw. (3408)
24 GnRH analog$.tw. (2085)
25 luteinizing hormone releasing agonist$.tw. (5)
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26 exp Menotropins/ (3017)
27 human menopausal gonadotropin$.tw. (1344)
28 or/13-27 (36003)
29 desensiti?ation.tw. (19633)
30 (long adj2 protocol).tw. (843)
31 (short adj2 protocol).tw. (406)
32 (ultra short adj2 protocol).tw. (5)
33 (long adj2 follicular).tw. (47)
34 (ultrashort adj2 protocol).tw. (11)
35 reduced dos$.tw. (3057)
36 down regulat$.tw. (89044)
37 downregulat$.tw. (64084)
38 (follicular adj5 luteal).tw. (2798)
39 high dose$.tw. (101864)
40 stop versus non stop.tw. (1)
41 prolonged protocol.tw. (5)
42 7 day.tw. (15537)
43 continu$ versus stop$.tw. (3)
44 short acting.tw. (5630)
45 early cessation.tw. (285)
46 early follicular.tw. (1652)
47 different phase$.tw. (7846)
48 daily.tw. (348977)
49 long acting.tw. (16507)
50 long luteal.tw. (52)
51 desensiti?e.tw. (1409)
52 suppression.tw. (170539)
53 suppress.tw. (64930)
54 (inhibition or inhibit).tw. (789675)
55 (long adj2 protocol$).tw. (1017)
56 (short adj2 protocol$).tw. (526)
57 or/29-56 (1536670)
58 12 and 28 and 57 (2202)
59 randomized controlled trial.pt. (370469)
60 controlled clinical trial.pt. (88141)
61 randomized.ab. (290565)
62 randomised.ab. (58371)
63 placebo.tw. (157118)
64 clinical trials as topic.sh. (169329)
65 randomly.ab. (210657)
66 trial.ti. (124866)
67 (crossover or cross-over or cross over).tw. (60254)
68 or/59-67 (936052)
69 exp animals/ not humans.sh. (3921813)
70 68 not 69 (863309)
71 58 and 70 (696)
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Appendix 4. EMBASE search
Database: Embase <1980 to 2015 Week 16>
Search Strategy:
1 exp embryo transfer/ or exp infertility therapy/ (75966)
2 exp female infertility/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (71995)
3 embryo transfer.tw. (10480)
4 in vitro fertili?ation.tw. (20223)
5 intracytoplasmic sperm injection$.tw. (6184)
6 (ivf or icsi).tw. (28413)
7 exp premature ovarian failure/ (2247)
8 (ovar$ adj2 stimulat$).tw. (6983)
9 (ovar$ adj2 hyperstimulat$).tw. (5230)
10 COH.tw. (1444)
11 or/1-10 (108706)
12 exp gonadorelin/ or exp gonadorelin agonist/ (36886)
13 exp buserelin acetate/ or exp buserelin/ (4583)
14 exp goserelin/ (5701)
15 exp leuprorelin/ (8556)
16 exp nafarelin acetate/ or exp nafarelin/ (1328)
17 exp triptorelin/ (3972)
18 gonadotrop?in-releasing hormone$.tw. (14213)
19 (buserelin or goserelin or leuprolide or nafarelin or triptorelin).tw. (5269)
20 (Lupron or Suprefact or Suprecor).tw. (2488)
21 (histrelin or Supprelin).tw. (114)
22 (Zoladex or deslorelin).tw. (2138)
23 (Suprelorin or Ovuplant).tw. (31)
24 Synarel.tw. (319)
25 GnRHa.tw. (1457)
26 GnRH-a.tw. (1070)
27 GnRH agonist$.tw. (4596)
28 GnRH analog$.tw. (2744)
29 luteinizing hormone releasing agonist$.tw. (7)
30 exp human menopausal gonadotropin/ (7971)
31 human menopausal gonadotrop?in$.tw. (2022)
32 or/12-31 (57973)
33 11 and 32 (13889)
34 desensiti?ation.tw. (21946)
35 (long adj2 protocol).tw. (1285)
36 (short adj2 protocol).tw. (584)
37 (ultra short adj2 protocol).tw. (8)
38 (long adj2 follicular).tw. (61)
39 (ultrashort adj2 protocol).tw. (13)
40 reduced dos$.tw. (4136)
41 down regulat$.tw. (108195)
42 downregulat$.tw. (79715)
43 (follicular adj5 luteal).tw. (2948)
44 high dose$.tw. (125377)
45 stop versus non stop.tw. (1)
46 prolonged protocol.tw. (5)
47 7 day.tw. (18760)
48 continu$ versus stop$.tw. (3)
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49 short acting.tw. (7235)
50 early cessation.tw. (343)
51 early follicular.tw. (1874)
52 different phase$.tw. (8761)
53 daily.tw. (436352)
54 long acting.tw. (20976)
55 long luteal.tw. (76)
56 desensiti?e.tw. (1555)
57 suppression.tw. (186085)
58 suppress.tw. (72208)
59 (inhibition or inhibit).tw. (859108)
60 (long adj2 protocol$).tw. (1526)
61 (short adj2 protocol$).tw. (742)
62 or/34-61 (1754598)
63 33 and 62 (3688)
64 Clinical Trial/ (829568)
65 Randomized Controlled Trial/ (338773)
66 exp randomization/ (61524)
67 Single Blind Procedure/ (18032)
68 Double Blind Procedure/ (112415)
69 Crossover Procedure/ (38335)
70 Placebo/ (236318)
71 Randomi?ed controlled trial$.tw. (95890)
72 Rct.tw. (13384)
73 random allocation.tw. (1288)
74 randomly allocated.tw. (19790)
75 allocated randomly.tw. (1896)
76 (allocated adj2 random).tw. (707)
77 Single blind$.tw. (13937)
78 Double blind$.tw. (138097)
79 ((treble or triple) adj blind$).tw. (351)
80 placebo$.tw. (193550)
81 prospective study/ (245030)
82 or/64-81 (1339414)
83 case study/ (25067)
84 case report.tw. (253821)
85 abstract report/ or letter/ (883698)
86 or/83-85 (1157110)
87 82 not 86 (1302183)
88 63 and 87 (1219)
Appendix 5. CINAHL search
EBSCO: 01.01.08 to 23.04.14.
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S33 S18 AND S32 70
S32 S19 OR S20 or S21 or S22 OR S23 OR S24 OR S25OR S26
OR S27 OR S28 OR S29 OR S30 OR S31
955,673
S31 TX allocat* random* 4,250
S30 (MH ”Quantitative Studies“) 13,306
S29 (MH ”Placebos“) 9,184
S28 TX placebo* 33,672
S27 TX random* allocat* 4,250
S26 (MH ”Random Assignment“) 39,015
S25 TX randomi* control* trial* 86,166
S24 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
764,433
S23 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 114
S22 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 0
S21 TX clinic* n1 trial* 171,126
S20 PT Clinical trial 77,731
S19 (MH ”Clinical Trials+“) 186,401
S18 S8 AND S17 157
S17 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR
S16
1,371
S16 TX (gonadotropin releasing hormone agonist*) 190
S15 TX (Luteinising hormone releasing hormone) 34
S14 TX GnRH a 129
S13 TX buserelin or TX leuprolin or TX leuprorelin or TX na-
farelin or TX triptorelin or TX Lupron or TX Zoladex or TX
deslorelin
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(Continued)
S12 TX (GnRH agonist*) 159
S11 TX Gonadorelin OR TX Leuprolide 1,015
S10 TX Goserelin 237
S9 (MM ”Gonadorelin“) OR (MM ”Leuprolide“) OR (MM
”Goserelin“)
590
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 3,731
S7 TX embryo* N3 transfer* 771
S6 TX ovar* N3 hyperstimulat* 336
S5 TX ovari* N3 stimulat* 246
S4 TX IVF or TX ICSI 1,249
S3 (MM ”Fertilization in Vitro“) 1,446
S2 TX vitro fertilization 2,852
S1 TX vitro fertilisation 266
Appendix 6. Information from the studies selected for the review
Trial characteristics
(1) Method and timing of randomisation:
• randomisation was adequate (e.g., by computer, random number tables, or drawing lots); or
• not clear (e.g., stated but not further described, or did not fall into one of the randomisation categories).
(2) Allocation concealment.
(3) Duration, timing, and location of the trial (single centre or multicentre trial), duration of follow up, and:
• outcome data used for primary analysis were complete (follow up to live birth), all randomised women were accounted for with
an intention-to-treat analysis;
• completeness of data uncertain; or
• outcome data incomplete, with 5% of the cycles commenced missing some outcome data.
(4) Co-intervention:
• other care provided with the intervention under study was equivalent in the treatment and control groups;
• issue of co-intervention was not considered; or
• co-intervention variations definitely existed.
(5) The presence of a power calculation:
(a) yes (prospective and valid or not valid); or
(b) no.
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Baseline characteristics of the studied groups
(a) Cause and duration of pre-existing subfertility
(b) Age of the women and parity
(c) Investigative work-up prior to in vitro fertilisation (IVF)
(d) Previously administered treatment(s)
Intervention
(a) Type of intervention and control comparator
(b) Dose and type of regime
(c) We differentiated between whether the studied population included all women undergoing assisted reproduction technology (ART)
or was limited to women who had responded poorly in a previous attempt or were expected to have a diminished response. As different
drug regimes of ovarian stimulation can lead to a variable ovarian response, data on the drugs employed was also extracted.
Outcomes
(a) Outcomes reported
(b) How outcomes were defined
(c) Timing of outcome measurement
WH A T ’ S N E W
Last assessed as up-to-date: 23 April 2015.
Date Event Description
24 July 2015 New citation required but conclusions have not changed The addition of 8 new studies did not lead to a change in
the conclusions of this review
24 July 2015 New search has been performed 8 studies were added in this update, and 1 co-author was
added. The text was thoroughly changed according to cur-
rent Menstrual Disorders and Subfertility Group guide-
lines
New included studies: Berker 2010; Chatillon-Boissier
2012; Ding 2013; Isikoglu 2007; Lin 2013; Sarhan 2013;
Sunkara 2014; and Zhang 2009.
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 8, 2011
130Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Date Event Description
11 January 2009 Amended Original review has been withdrawn, and a new protocol has been
published
Title changed back from ’Long versus short gonadotropin releas-
ing hormone agonist protocols for pituitary desensitization in as-
sisted reproduction cycles’ to ’Gonadotrophin-releasing hormone
agonist protocols for pituitary suppression in assisted reproductive
treatment’
11 December 2008: Title changed from ’Gonadotrophin-releas-
ing hormone agonist protocols for pituitary down regulation in as-
sisted reproductive treatment’ to ’Long versus short gonadotropin
releasing hormone agonist protocols for pituitary desensitization
in assisted reproduction cycles’
12 November 2007 New citation required and major changes Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
AM: initiated and conceptualised the protocol; undertook data searching, selection of studies, data extraction, drafting of the first
update of the review, assessment of studies for inclusion, interpretation and analysis of data, and editing of the second update.
CS: co-drafted the protocol; undertook data searching, selection of studies, and data extraction, and wrote the second update.
AG: co-drafted the protocol; undertook data searching, selection of studies, and data extraction.
GB: undertook data searching, selection of studies, and data extraction in the second update.
SB: overall supervision and editing of the review.
Timeline
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S O U R C E S O F S U P P O R T
Internal sources
• Assisted Reproduction Unit, University of Aberdeen, UK.
• Assisted Reproduction Unit, 3rd Department of Obstetrics and Gynecology, University of Athens, Greece.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Ourprotocolmentioned one of the comparison groups as gonadotrophin-releasinghormone agonists (GnRHa) versus placebo.However,
there is a review of randomised controlled trials (RCTs) on this topic (Fields 2013) suggesting that use of GnRHa is associated with a
better outcome in assisted reproduction technology (ART). The current review intended to explore which protocol was better.
A short protocol versus a short stop protocol was not listed in the initial comparison groups. However, since we were looking at all
protocols for GnRHa for pituitary down-regulation, we felt it was appropriate to include studies comparing these groups.
The original review was withdrawn, and a new protocol was published.
11 December 2008: The title changed from ’Long versus short gonadotropin releasing hormone agonist protocols for pituitary
desensitization in assisted reproduction cycles’ to ’Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in
assisted reproductive treatment’.
A further title change from ’Gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproductive
treatment’ to ’Gonadotropin releasing hormone agonist protocols for pituitary suppression in assisted reproduction’ was agreed in 2011.
31 August 2014: we added two comparisons:
• long protocol: discontinuing versus continuing GnRHa after HCG administration; and
• long protocol: administration of GnRHa for fewer than versus more than 18 days before stimulation.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Reproductive Techniques, Assisted; Buserelin [administration & dosage]; Clinical Protocols; Drug Administration Schedule; Fertility
Agents, Female [∗administration & dosage]; Gonadotropin-Releasing Hormone [∗agonists]; Leuprolide [administration & dosage];
Live Birth; Luteinizing Hormone [∗antagonists & inhibitors; metabolism]; Ovulation Induction [∗methods]; Pituitary Gland [∗drug
effects]; Pregnancy Rate; Randomized Controlled Trials as Topic; Triptorelin Pamoate [administration & dosage]
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MeSH check words
Female; Humans; Pregnancy
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